Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection by Sanders, Sharon L et al.
Bond University
Research Repository
Immunoglobulin treatment for hospitalised infants and young children with respiratory
syncytial virus infection
Sanders, Sharon L; Agwan, Sushil; Hassan, Mohamed; van Driel, Mieke L; Del Mar, Chris B
Published in:
Cochrane database of systematic reviews (Online)
DOI:
10.1002/14651858.CD009417.pub2
Published: 26/08/2019
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Sanders, S. L., Agwan, S., Hassan, M., van Driel, M. L., & Del Mar, C. B. (2019). Immunoglobulin treatment for
hospitalised infants and young children with respiratory syncytial virus infection. Cochrane database of
systematic reviews (Online), 2019(8), [CD009417]. https://doi.org/10.1002/14651858.CD009417.pub2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 09 Oct 2020
Cochrane Database of Systematic Reviews
Immunoglobulin treatment for hospitalised infants and young
children with respiratory syncytial virus infection (Review)
Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB
Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB.
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
Cochrane Database of Systematic Reviews 2019, Issue 8. Art. No.: CD009417.
DOI: 10.1002/14651858.CD009417.pub2.
www.cochranelibrary.com
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
18DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Immunoglobulins versus placebo, Outcome 1 Mortality (any cause during hospitalisation or
follow-up). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.2. Comparison 1 Immunoglobulins versus placebo, Outcome 2 Length of hospitalisation (days). . . . . 45
Analysis 1.3. Comparison 1 Immunoglobulins versus placebo, Outcome 3 Adverse events of any severity or seriousness. 46
Analysis 1.4. Comparison 1 Immunoglobulins versus placebo, Outcome 4 Serious adverse events. . . . . . . . 47
Analysis 1.5. Comparison 1 Immunoglobulins versus placebo, Outcome 5 Need for mechanical ventilation. . . . 48
Analysis 1.6. Comparison 1 Immunoglobulins versus placebo, Outcome 6 Duration of mechanical ventilation. . . 49
Analysis 1.7. Comparison 1 Immunoglobulins versus placebo, Outcome 7 Need for supplemental oxygen. . . . . 49
Analysis 1.8. Comparison 1 Immunoglobulins versus placebo, Outcome 8 Duration of supplemental oxygen. . . . 50
Analysis 1.9. Comparison 1 Immunoglobulins versus placebo, Outcome 9 Need for ICU admission. . . . . . . 51
Analysis 1.10. Comparison 1 Immunoglobulins versus placebo, Outcome 10 Duration of stay in the ICU. . . . . 52
52ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iImmunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Immunoglobulin treatment for hospitalised infants and young
children with respiratory syncytial virus infection
Sharon L Sanders1, Sushil Agwan2, Mohamed Hassan2, Mieke L van Driel1,3,4, Chris B Del Mar1
1Centre for Research in Evidence-Based Practice (CREBP), Bond University, Gold Coast, Australia. 2Gold Coast University Hos-
pital, Gold Coast, Australia. 3Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
4Department of Family Medicine and Primary Health Care, Ghent University, Ghent, Belgium
Contact address: Sharon L Sanders, Centre for Research in Evidence-Based Practice (CREBP), Bond University, University Drive,
Robina, Gold Coast, Queensland, 4229, Australia. ssanders@bond.edu.au, ssanders@bond.edu.au.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: New, published in Issue 8, 2019.
Citation: Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB. Immunoglobulin treatment for hospitalised infants and young
children with respiratory syncytial virus infection. Cochrane Database of Systematic Reviews 2019, Issue 8. Art. No.: CD009417. DOI:
10.1002/14651858.CD009417.pub2.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Millions of children are hospitalised due to respiratory syncytial virus (RSV) infection every year. Treatment is supportive, and current
therapies (e.g. inhaled bronchodilators, epinephrine, nebulised hypertonic saline, and corticosteroids) are ineffective or have limited
effect. Respiratory syncytial virus immunoglobulin is sometimes used prophylactically to prevent hospital admission from RSV-related
illness. It may be considered for the treatment of established severe RSV infection or for treatment in an immunocompromised host,
although it is not licenced for this purpose. It is unclear whether immunoglobulins improve outcomes when used as a treatment for
established RSV infection in infants and young children admitted to hospital.
Objectives
To assess the effects of immunoglobulins for the treatment of RSV-proven lower respiratory tract infections in children aged up to three
years, admitted to hospital.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory
Infections Group’s Specialised Register, Ovid MEDLINE, Embase, CINAHL, and Web of Science (from inception to 6 November
2018) with no restrictions. We searched two trial registries for ongoing trials (to 30 March 2018) and checked the reference lists of
reviews and included articles for additional studies.
Selection criteria
Randomised controlled trials comparing immunoglobulins with placebo in hospitalised infants and children aged up to three years
with laboratory-diagnosed RSV lower respiratory tract infection.
Data collection and analysis
Two review authors independently selected trials, assessed risk of bias, and extracted data. We assessed evidence quality using GRADE.
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Main results
We included seven trials involving 486 infants and children aged up to three years. The immunoglobulin preparations used in these
trials included anti-RSV immunoglobulin and the monoclonal antibody preparations palivizumab and motavizumab. We assessed the
primary outcomes of mortality, length of hospital stay, and adverse events as providing low- or very low-certainty evidence due to risk
of bias and imprecision. All trials were conducted at sites in high-income countries (USA, Chile, New Zealand, Australia), with two
studies including a site in a middle-income country (Panama). Five of the seven studies were “supported” or “sponsored” by the trial
drug manufacturers.
We found no evidence of a difference between immunoglobulins and placebo formortality (risk ratio (RR) 0.87, 95%confidence interval
(CI) 0.14 to 5.27; 3 trials; 196 children; 4 deaths; 2 deaths amongst 98 children receiving immunoglobulins, and 2 deaths amongst 98
children receiving placebo. One additional death occurred in a fourth trial, however, the study group of the child was not known and
the data were not included in the analysis; very low-certainty evidence), and length of hospitalisation (mean difference −0.70, 95%
CI −1.83 to 0.42; 5 trials; 324 children; low-certainty evidence). There was no evidence of a difference between immunoglobulins
and placebo in adverse events of any severity or seriousness (reported in five trials) or serious adverse events (four trials) (RR for any
severity 1.18, 95% CI 0.78 to 1.78; 340 children; low-certainty evidence, and for serious adverse events 1.08, 95% CI 0.65 to 1.79;
238 children; low-certainty evidence).
We found no evidence of a significant difference between immunoglobulins and placebo for any of our secondary outcomes. We
identified one ongoing trial.
Authors’ conclusions
We found insufficient evidence of a difference between immunoglobulins and placebo for any review outcomes.We assessed the evidence
for the effects of immunoglobulins when used as a treatment for RSV lower respiratory tract infection in hospitalised infants and young
children as of low or very low certainty due to risk of bias and imprecision. We are uncertain of the effects of immunoglobulins on
these outcomes, and the true effect may be substantially different from the effects reported in this review. All trials were conducted in
high-income countries, and data from populations in which the rate of death from RSV infection is higher are lacking.
P L A I N L A N G U A G E S U M M A R Y
Drug treatment for respiratory syncytial virus lung infections
Review question
Does the use of immunoglobulins in very young children hospitalised with a respiratory syncytial virus (RSV) lung infection reduce
deaths and hospital stay without increased adverse events, compared with placebo (a similar-appearing fake drug that has no effect)?
Background
Respiratory syncytial virus is a common virus that can infect lungs and airways. Millions of children are treated in hospital each year
for RSV, which can result in severe illness and death. The majority of these deaths occur in low-income countries. In high-income
countries, the majority of deaths associated with RSV lung infection occur in infants and young children with other illnesses.
Immunoglobulins, also known as antibodies, are a type of molecule normally produced by white blood cells when an infection is
present. Immunoglobulins may recognise and attach to viruses (such as RSV) and help destroy them. Immunoglobulins can be produced
artificially and given to children who are not making their own RSV antibodies. Some studies have shown that immunoglobulins are
helpful in preventing RSV infection in children at high risk of becoming infected. They may also be used as a treatment when an RSV
infection is already present, but the effectiveness and safety of immunoglobulins for this use is unknown.
Search date
We searched for evidence up to 6 November 2018.
Study characteristics
We included seven randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups
using a random method) that compared the effects of immunoglobulins with placebo in 486 young children hospitalised with RSV
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lung infections. All trials were conducted at sites in the USA; three trials included some children from South American countries (Chile
and Panama); and one trial also included children fromNew Zealand and Australia. The trials were published between 1987 and 2014.
Study funding sources
Five trials were supported by the manufacturer of the immunoglobulin tested in the studies. One trial was supported by a government
agency, and one trial did not describe how it was funded.
Key results
Immunoglobulins did not appear to be more effective than placebo in preventing deaths among young children with RSV infection,
although few deaths occurred in the trials. Immunoglobulins given to children hospitalised with RSV lung infection did not decrease
the time spent in hospital. Children treated with immunoglobulins experienced adverse effects of any severity or seriousness and adverse
effects considered to be serious (such as respiratory failure) as often as children treated with placebo. There was no difference between
immunoglobulins and placebo for any other outcomes measured in the trials, such as the need for oxygen or admission to the intensive
care unit. Data from populations in which the rate of death from RSV infection is higher are lacking.
Quality of the evidence
The quality of the evidence was low or very low, which means that the true effect of immunoglobulin treatment for young children in
hospital with RSV lung infection may be very different from the findings of this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Immunoglobulins compared to placebo for treatment of respiratory syncytial virus infection
Patient or population: children with respiratory syncyt ial virus infect ion
Setting: hospital
Intervention: immunoglobulins
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with immunoglob-
ulins
Mortality
f ollow-up: range 30
days to 60 days
20 per 1000 18 per 1000
(3 to 108)
RR 0.87
(0.14 to 5.27)
196
(3 RCTs)
⊕©©©
VERY LOW 1
Intervent ions: mono-
clonal immunoglobulin
palivizumab in 2 trials,
t it res of neutralising an-
t ibodies to RSV in 1 trial
Sett ings: study sites
in high-income country
(USA) and
middle-income country
(Panama)
Length of hospitalisa-
tion (days)
follow-up: range 30
days to 60 days
Mean length of hospi-
talisat ion range 5 to 12
days
MD 0.7 fewer
(1.83 fewer to 0.42
more)
- 324
(5 RCTs)
⊕⊕©©
LOW 2
Intervent ions: mono-
clonal immunoglobu-
lin palivizumab in
2 trials, monoclonal
immunoglobulin mo-
tavizumab in 1 trial,
t it res of neutralising an-
t ibodies to RSV in 2 tri-
als
Sett ings: study sites
in high-income coun-
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t ries (USA, Chile) and
middle-income country
(Panama)
Adverse events
f ollow-up: range 30
days to 90 days
413 per 1000 488 per 1000
(322 to 736)
RR 1.18
(0.78 to 1.78)
340
(5 RCTs)
⊕⊕©©
LOW 3
Intervent ions: mono-
clonal immunoglobu-
lin palivizumab in
2 trials, monoclonal
immunoglobulin mo-
tavizumab in 2 trials,
t it res of neutralising an-
t ibodies to RSV in 1 trial
Sett ings: study sites
in high-income coun-
tries (USA, Chile, New
Zealand, Australia) and
middle-income country
(Panama)
Serious adverse events
f ollow-up: range 30
days to 90 days
202 per 1000 218 per 1000
(131 to 362)
RR 1.08
(0.65 to 1.79)
238
(4 RCTs)
⊕⊕©©
LOW 3
Intervent ions: mono-
clonal immunoglobu-
lin palivizumab in
2 trials, monoclonal
immunoglobulin mo-
tavizumab in 2 trials
Sett ings: study sites
in high-income coun-
tries (USA, Chile, New
Zealand, Australia) and
middle-income country
(Panama)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; RSV: respiratory syncyt ial virus
5
Im
m
u
n
o
g
lo
b
u
lin
tre
a
tm
e
n
t
fo
r
h
o
sp
ita
lise
d
in
fa
n
ts
a
n
d
y
o
u
n
g
c
h
ild
re
n
w
ith
re
sp
ira
to
ry
sy
n
c
y
tia
l
v
iru
s
in
fe
c
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded to very low due to serious risk of bias (unclear random sequence generat ion, select ive report ing, and other
bias) and very serious imprecision (very small sample size compared to the opt imal information size, few events, and wide
conf idence interval overlapping zones of no ef fect as well as potent ial harm or benef it ).
2Downgraded to low due to serious risk of bias (unclear random sequence generat ion, select ive report ing, and other bias) and
serious imprecision.
3Downgraded to low due to serious risk of bias (unclear random sequence generat ion, select ive report ing, and other bias) and
serious imprecision (small sample size compared to the opt imal information size and wide conf idence intervals overlapping
zones of no ef fect as well as potent ial harm or benef it ).
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B A C K G R O U N D
Description of the condition
The respiratory syncytial virus (RSV) is the most common cause
of acute lower respiratory tract infections (LRTI), such as bron-
chiolitis and pneumonia, in infancy and childhood (Nair 2010).
Nearly all children will have been infected with RSV by the age of
two years (Greenough 2001). Respiratory syncytial virus infection
carries a substantial disease burden, with 33 million (uncertainty
range 22 to 50 million) episodes of RSV-associated acute LRTI
globally in 2015, resulting in about three million hospital admis-
sions and approximately 59,000 deaths (Shi 2017). The societal
burden associated with caring for the ill and healthcare costs due
to RSV infection are substantial (Langley 1997; Paramore 2004).
The clinical manifestations of RSV infection vary according to
age and health status. Amongst children aged over three years and
adults, RSV causes only mild acute respiratory symptoms (such
as common cold, sore throat, headache, cough, low-grade fever,
and malaise) (Mayo Clinic 2017). However, about 20% to 30%
of younger children presenting with these symptoms can progress
rapidly to diffuse small airways diseasewith low-grade fever, cough,
wheezing, shortness of breath, decreased oral intake, and dif-
fuse crackles/rales on chest auscultation (American Academy of
Pediatrics 2015). Infants aged up to six weeks may present with
a non-specific sepsis-like picture (Oray-Schrom 2003). Apnoea
(transient period of breathing cessation) may also be present in
these infants (Ralston 2009). Severe cases of RSV infection in
young children and infants can cause oxygen starvation (hypoxia)
and acute respiratory (ventilatory) failure, which may need me-
chanical ventilation in an intensive care unit. Most children with
RSV infection make a full recovery, but some develop an increased
risk of wheezing, asthma, and impaired lung function later in life
(Zomer-Kooijker 2014).
Treatment of acute RSV infection is primarily supportive, and
includes suction to remove airways secretions, administration of
supplemental oxygen, and fluid replacement (American Academy
of Pediatrics 2018). Interventional agents are largely ineffective
or of limited effectiveness. The evidence for inhaled bronchodila-
tor therapy with beta-agonists is unconvincing for bronchiolitis
(Gadomski 2014), and there is insufficient evidence to support the
use of epinephrine for the treatment of bronchiolitis amongst chil-
dren admitted to hospital (Hartling 2011). Hypertonic saline and
corticosteroids are also used. Nebulised hypertonic saline solution
has a modest effect on length of hospital stay amongst infants hos-
pitalised with acute bronchiolitis (Zhang 2017), and systemic or
inhaled glucocorticoids have not been found to be effective for this
condition (Fernandes 2013). The effects of the antiviral therapy
ribavirin in children with respiratory infections caused by RSV
are unclear, and ribavirin is currently reserved for immunosup-
pressed children with severe RSV infection (American Academy
of Pediatrics 2018). The World Health Organization (WHO) has
targeted RSV for vaccine development (Broadbent 2015).
Description of the intervention
Immunogloblin therapy involves the administration of prepara-
tions containing high levels of immunoglobulins, or antibodies.
Administration of these antibodies confers passive resistance to
infection by increasing the quantity or quality of antibodies the
individual possesses. Immunoglobulin therapymay also be used to
reduce the severity of symptoms of disease in autoimmune disor-
ders (e.g. Guillain-Barre syndrome), secondary immunodeficien-
cies (e.g. HIV), and acute infections (Jolles 2005). Immunoglob-
ulin preparations for RSV contain high concentrations of anti-
bodies against RSV. These can be pooled preparations, whereby
the preparation is derived from the plasma of donors with natu-
rally high circulating levels of RSV neutralising antibodies. These
preparations also contain neutralising antibodies to other viruses
and bacteria. Alternatively, the preparation can comprise human-
ised monoclonal antibodies directed only against the RSV-F fu-
sion protein expressed on the surface of the RSV viron (Griffiths
2017).
Palivizumab (Synagis, MedImmune) is a monoclonal antibody
preparation administered as an intramuscular injection (Synagis
2017). It was approved by the US Food and Drug Administra-
tion (FDA) for RSV prophylaxis of high-risk children in 1998,
and has since received approval in over 45 other countries (Resch
2017). In randomised controlled trials, palivizumab reduced hos-
pitalisations for RSV in children with congenital heart disease
(risk ratio reduction (RRR) 0.45) (Feltes 2003), prematurity (RRR
0.78), and bronchopulmonary dysplasia (RRR 0.39). The Amer-
ican Academy of Pediatrics recommends immunoglobulin pro-
phylaxis for high-risk infants and children (American Academy of
Pediatrics 2014). Recommendations for palivizumab prophylaxis
differ globally because of its high cost (USD 3000 to 5000 per
child per year) (Wang 2011). Palivizumab is not licenced for the
treatment of established RSV infection. However, it has nonethe-
less been used to treat children with severe infection or to prevent
progression of the disease (Hu 2010; Turner 2014).
In 1996, RSV immune globulin intravenous (RSV-IGIV,
RespiriGam, MedImmune) was approved by the FDA for use in
the prevention of severe RSV infections in infants and children
aged up to 24 months with bronchopulmonary dysplasia or his-
tory of premature birth following two randomised controlled tri-
als in these high-risk infants. RSV-IGIV administered monthly
during the RSV season resulted in a 40% to 65% reduction in
hospitalisation rates (Groothuis 1993; PREVENT 1997). RSV-
IGIV was superseded by palivizumab in 2004.
Motavisumab is a monoclonal antibody against RSV that was de-
rived from palivizumab in the early 2000s. It has been reported
to offer greater potency against RSV in animal studies (Mejías
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2005). However, its development was discontinued in 2010 after
the FDA declined the manufacturer’s request for licensure due to
concerns about safety and non-inferiority to palivizumab.
How the intervention might work
Immunoglobulins provide passive immunity when the antibodies
bind and neutralise viral proteins responsible for viral attachment
to cells (G protein) and cell fusion (F protein) (Roche 2003),
which reduces viral replication (Rodriguez 1997). Palivizumab is a
humanised monoclonal antibody specific for the envelope fusion
protein (RS-F) of RSV. As viruses need to fuse with living cells to
replicate, this would reduce viral replication in the lungs of those
infected with RSV.
Why it is important to do this review
Therapy forRSV infectionof the lower respiratory tract in children
is primarily supportive, with existing interventional agents not
generally recommended or indicated. Although immunoglobulins
are currently licenced for the prevention of RSV LRTI only, they
may also be used as a management strategy. As such, an assessment
of the efficacy and safety of immunoglobulins as a treatment for
established RSV infection in children was necessary.
O B J E C T I V E S
To assess the effects of immunoglobulins for the treatment of RSV-
proven LRTIs in children aged up to three years, admitted to
hospital.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) that compared im-
munoglobulin treatment with a placebo control.
Types of participants
Infants and children (aged up to three years) hospitalised for bron-
chiolitis, pneumonia, or other LRTI with laboratory-documented
RSV infection.
Types of interventions
Treatments involving infusions with immunoglobulins. We did
not apply any limits regarding immunoglobulin type, dose, or
method of administration. The comparator was placebo.
Types of outcome measures
Primary outcomes
1. Mortality from any cause occurring during hospitalisation
or follow-up.
2. Length of hospitalisation.
3. Adverse events. We used definitions applied by study
investigators for adverse events and serious adverse events. These
were:
i) adverse events: the number of participants
experiencing one or more adverse event of any severity or
seriousness during the trial or follow-up. Adverse events were any
adverse changes from baseline occurring after study drug
administration. These events may or may not have been related
to the study drug; and
ii) serious adverse events: the number of participants
experiencing one or more adverse events considered by study
investigators to be serious in nature. These were events that
resulted in a substantial impairment of baseline function or
death, required or prolonged hospitalisation, or were otherwise
considered an important medical event, during the trial or
follow-up.
Secondary outcomes
1. Need for mechanical ventilation (for participants in studies
where requirement for mechanical ventilation was not a study
entry criterion).
2. Duration of mechanical ventilation (for those ventilated).
3. Need for supplemental oxygen.
4. Duration of supplemental oxygen (for those receiving
supplemental oxygen).
5. Need for intensive care unit (ICU) admission.
6. Duration of stay in the ICU (for those admitted to the
ICU).
7. Pulmonary function measured by spirometry.
8. Rehospitalisation for recurrent breathing difficulties in the
long term.
9. The occurrence of reactive airway disease in the long term.
Search methods for identification of studies
Electronic searches
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We searched the Cochrane Central Register of Controlled Tri-
als (Issue 10, October 2018 accessed 6 November 2018) in the
Cochrane Library, which includes theCochrane Acute Respiratory
Infections Group’s Specialised Register, Ovid MEDLINE (1946
to 6 November 2018), Embase (Elsevier) (1974 to 6 November
2018), CINAHL (EBSCO) (1982 to 6 November 2018), and
Web of Science (Clarivate Analytics) (1985 to 6 November 2018).
There were no language restrictions.
We used the search strategy in Appendix 1 to search MEDLINE
and CENTRAL. We combined the MEDLINE search strategy
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision);Ovid format (Lefebvre 2011).
We adapted the search strategy to search Embase (Appendix 2),
CINAHL (Appendix 3), and Web of Science (Appendix 4).
Searching other resources
We searched two trials registers (US National Institutes of Health
Ongoing Trials Register ClinicalTrials.gov ( clinicaltrials.gov) and
the World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( apps.who.int/trialsearch/)) for
completed and ongoing trials on 30March 2018. We conducted a
forward citation search of included studies via Web of Science on
30 March 2018. We also searched the reference lists of included
trials and relevant review articles.
Data collection and analysis
Selection of studies
Two review authors (SLS and one of the current review authors
(CDM or MD) or one of two review authors who worked on an
earlier draft of the review, (MK or MG)) independently screened
titles and abstracts. We retrieved full-text study reports of titles
and abstracts considered by two review authors to be potentially
relevant. Two review authors (SLS and either CDMorMDorMK
or MG) independently screened the retrieved full-text reports to
identify studies for inclusion, and recorded the reasons for exclu-
sion of ineligible studies. Any disagreements were resolved through
discussion or by consultation with a third review author (either
CDM or MD) when necessary.
Data extraction and management
Two review authors (SLS and CDM or MK) independently ex-
tracted the following data from the included studies: study de-
sign and setting; location of study, inclusion and exclusion crite-
ria, and characteristics of the participants; characteristics of the
intervention and comparison (type of immunoglobulin, dosage,
method of administration); and the primary and secondary out-
comes specified and time points reported. Disagreements regard-
ing data extraction were resolved by discussion. One review author
(SLS) entered data into RevMan 5 (Review Manager 2014). Two
other review authors (SA and MH) verified data extraction and
entry.
Assessment of risk of bias in included studies
Two review authors (SLS and MD or CDM) independently as-
sessed risk of bias for each study using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). Disagreements were resolved by discussion with a third re-
view author (MD or CDM). We considered the following seven
domains in our ’Risk of bias’ assessment.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias including bias related to study funding sources.
We assessed each study as being at low, high, or unclear risk of
bias for each domain and provided a quote from the study report
together with a justification for our judgement in the ’Risk of bias’
table. For other bias relating to study funding sources, we rated
a study as at high risk of bias if the report indicated that it was
funded, supported, or sponsored by parties that may have had a
vested interest in the results of the study (e.g. drug manufacturer).
We rated studies as at unclear risk of bias if study authors or
members of the study group had potential conflicts of interest (e.g.
were employees of the drug manufacturer). We took into account
the risk of bias for the studies contributing to each outcome when
considering treatment effects.
Measures of treatment effect
We used Cochrane’s Review Manager 5 (RevMan 5) software for
all analyses (Review Manager 2014). We planned to calculate risk
ratios (RRs) and 95% confidence intervals (CIs) for binary out-
comes (i.e. mortality and adverse events). For continuous out-
comes, such as length of hospitalisation, we calculated the mean
difference (MD) and 95% CIs.
Unit of analysis issues
The participant was the unit of analysis in our meta-analysis. We
planned to apply any corrections for clustering as described in the
Cochrane Handbook for Systematic Reviews of Interventions if the
unit of randomisation was not the same as the unit of analysis in
cluster-randomised trials (Higgins 2011).
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Dealing with missing data
For continuous outcomes where no standard deviations (SD) were
reported, we obtained them from standard errors for group means
using the method specified in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). For continuous out-
comes where median was reported instead of the group mean, we
described outcomes for that study narratively for each outcome
(see Results). For the primary outcome, length of hospital stay,
where median was reported instead of group mean, we used the
median and range to calculate a mean and SD employing the
method of Hozo (Hozo 2005). The study was then included in
the meta-analysis in a post hoc sensitivity analysis.
Assessment of heterogeneity
We assessed the presence of clinical heterogeneity by comparing
populations (age, immune status, severity of disease), interven-
tions, and outcomes before deciding whether it was appropriate to
pool data. We planned to describe studies that we judged to be too
clinically heterogeneous and not combine them in a meta-anal-
ysis. We assessed studies providing data on each outcome with-
out substantial clinical heterogeneity for statistical heterogeneity
by means of the I² statistic (I² greater than 50% was considered
substantial heterogeneity) (Higgins 2011).
Assessment of reporting biases
We planned to assess publication bias using a funnel plot test if
more than 10 studies contributed data. However, there were too
few included studies to enable this assessment.
Data synthesis
We pooled outcome data from studies that we judged to be clini-
cally homogeneous using RevMan 5 (Review Manager 2014). As
we considered that a single true effect was not plausible due to
variation in populations and interventions, we pooled study data
using a random-effects model.
For studies with more than one placebo or intervention group, we
combined data according to the formula in Section 7.7.3.8 Com-
bining groups of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
We planned to report the number of participants who experienced
one or more adverse events (whether the event was considered se-
rious or not, or whether the event was attributed by the investiga-
tors to the study interventions or not) rather than the number of
adverse events.
GRADE and ’Summary of findings’ table
We created Summary of findings for the main comparison for the
following outcomes: mortality, length of hospitalisation, adverse
events, and serious adverse events. We assessed the certainty of the
evidence for each outcome included in the ’Summary of findings’
table using the GRADE evidence grading system as described in
the GRADE Handbook, Schünemann 2013, and Section 12.2 of
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011).We used GRADEproGDT software (GRADEpro
GDT). We took the following factors into consideration when
deciding whether or not to downgrade the certainty of evidence
for each outcome: risk of bias, inconsistency of results, indirectness
of evidence, imprecision of results, and publication bias.
We considered the number of events, the size of the confidence in-
tervals and calculated a posteriori the optimal information size to
assess imprecision. We considered a difference of 25% as the min-
imal clinically important difference for dichotomous outcomes to
determine optimal information size (this is the threshold recom-
mended by GRADE when there is no compelling rationale for
an alternate threshold) (Schünemann 2013). For the continuous
outcome length of stay, we considered one day as the minimum
clinically important difference (the judgement that reductions in
stay of one day are clinically important was based on the clinical
experience of the review authors and agreed upon through discus-
sion). Calculation of the optimal information size depends upon
this difference and the resulting sample size required (Schünemann
2013). We assumed a 3% risk of mortality (median control event
rate from trials providing these data); 30% risk of adverse event
(median control event rate from trials providing these data); and
an SD of 6.4 (median control SD from trials providing these data)
with a power of 80% and a two-sided alpha of 0.05. One review
author (SLS) initially applied the GRADE criteria and then dis-
cussed the certainty of evidence ratings with other review authors
(CDM,MD). Final decisions on the ratings were reached through
discussion and consensus. We justified all decisions to downgrade
the certainty of studies in table footnotes.
Subgroup analysis and investigation of heterogeneity
We planned to conduct the following subgroup analyses.
1. Children aged six months or less versus children older than
six months.
2. Children with a recurrent episode of RSV versus first
episode.
3. Immunocompromised versus non-immunocompromised
children.
4. Children with congenital heart disease.
5. Children with bronchopulmonary dysplasia.
6. Palivizumab versus other immunoglobulin preparations.
However, the small number of included studies precluded these
analyses.
Sensitivity analysis
We planned to perform sensitivity analyses to assess the impact of
excluding studies at high risk of bias for allocation concealment
based on the ’Risk of bias’ assessment for the primary outcome
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estimates. However, all studies were judged to be at either low
or unclear risk of bias for allocation concealment, so sensitivity
analysis was not performed.
R E S U L T S
Description of studies
Results of the search
Database searches (conducted 6 November 2018) yielded 4399
records, and 38 records were identified in trials register searches
(conducted 30 March 2018). We screened 3336 records for el-
igibility after removal of duplicates, of which 15 were retrieved
for full-text screening. We also obtained two additional records
identified from screening reference lists of previously published
reviews and forward citation searching the included studies for
full-text screening. We therefore screened 17 full-text records,
and included seven studies in the review (Hemming 1987; Lagos
2009; Malley 1998; Ramilo 2014; Rodriguez 1997a; Rodriguez
1997b; Sáez-Llorens 2004). We identified one ongoing study
(NCT02442427). A flow diagram of the study selection process
is presented in Figure 1.
Figure 1. Study flow diagram.
Included studies
A full description of all seven included studies is provided in
Characteristics of included studies.
Design
All seven included studies were RCTs that used a parallel-group de-
sign. Three trials compared two or more different doses of the in-
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tervention with placebo (Lagos 2009; Ramilo 2014; Sáez-Llorens
2004), with escalation to a higher dose after a specified period of
time in the absence of toxicity or serious adverse events in two
studies (Lagos 2009; Sáez-Llorens 2004).
Participants
A total of 486 children were included in the seven trials; the num-
ber of children per trial ranged from 31 to 118. All trials were con-
ducted at sites in high-income countries, with two trials includ-
ing a study site in a middle-income country (Panama). Six trials
were conducted in the USA (Hemming 1987; Lagos 2009;Malley
1998; Rodriguez 1997a; Rodriguez 1997b; Sáez-Llorens 2004);
two of these studies had sites in South America (Sáez-Llorens 2004
in Panama and Lagos 2009 in Chile). One trial was reported to
have been conducted at “multiple sites”, which included the USA,
New Zealand, Chile, Panama, and Australia (Ramilo 2014).
The studies included children and infants hospitalised for pneu-
monia, bronchiolitis, or other LRTI with a documented positive
RSV test. Participantswere described as “previously healthy” infive
studies (Hemming 1987; Lagos 2009; Ramilo 2014; Rodriguez
1997b; Sáez-Llorens 2004); at “high risk for severeRSV infections”
in one study (Rodriguez 1997a); and were a mix of previously
healthy children and children with “chronic medical conditions”
in one study (Malley 1998). High-risk infants included those with
severe bronchopulmonary dysplasia, chronic lung disease, con-
genital heart disease, or prematurity (< 32 weeks gestational age).
One study included only children who required intubation and
mechanical ventilation at study entry (Malley 1998), and another
study included children who required more than 30% supplemen-
tal oxygen (Sáez-Llorens 2004). Participants were aged up to 12
months in one study (Ramilo 2014); up to two years at randomi-
sation in five studies (Lagos 2009;Malley 1998; Rodriguez 1997a;
Rodriguez 1997b; Sáez-Llorens 2004); and one study did not re-
port an upper age limit, but included children with body weight
up to 10 kg (Hemming 1987).
Interventions
The included studies evaluated different doses and types of im-
munoglobulin preparations. Three studies used titres of neutralis-
ing antibody toRSV administered intravenously (Hemming 1987;
Rodriguez 1997a; Rodriguez 1997b), at doses of 1500 mg per kg
of body weight in Rodriguez 1997b and Rodriguez 1997a and
2 g per kg of body weight in Hemming 1987. The monoclonal
immunoglobulin motavizumab was administered intravenously in
two studies at doses of 3 mg, 15 mg, or 30 mg per kg of body
weight in Lagos 2009 and at doses of 30 mg or 100 mg per kg of
body weight in Ramilo 2014. The monoclonal immunoglobulin
palivizumab was administered intravenously at doses of 5 mg and
15 mg per kg in one study (Sáez-Llorens 2004), and at doses of
15 mg per kg in another study (Malley 1998).
Placebo was normal saline (0.9% sodium chloride) or half-nor-
mal saline (0.45%) in three studies, Lagos 2009; Malley 1998;
Sáez-Llorens 2004, and albumin (0.5% or 6%) in three studies
(Hemming 1987; Rodriguez 1997a; Rodriguez 1997b). The com-
position of the placebo was not stated in one study (Ramilo 2014).
None of the studies provided detail on who was involved in de-
livering the interventions to participants. Only two studies with
multiple study sites within the same country stated that “methods
were standardized for all centres” (Rodriguez 1997a; Rodriguez
1997b).
Outcome measures
Four studies reported that deaths occurred during the trial or
the follow-up period (Hemming 1987; Malley 1998; Rodriguez
1997a; Sáez-Llorens 2004). All seven included studies reported
the duration of hospitalisation. Six studies reported the number
of adverse events that occurred in the study groups (Lagos 2009;
Malley 1998; Ramilo 2014; Rodriguez 1997a; Rodriguez 1997b;
Sáez-Llorens 2004). Five of six studies that involved children who
did not require mechanical ventilation at study entry reported the
need for mechanical ventilation (Hemming 1987; Lagos 2009;
Ramilo 2014; Rodriguez 1997a; Rodriguez 1997b). Five stud-
ies reported the duration of mechanical ventilation (Lagos 2009;
Malley 1998; Ramilo 2014; Rodriguez 1997a; Rodriguez 1997b).
Four of five studies involving children who did not require intuba-
tion, mechanical ventilation, or supplemental oxygen at study en-
try reported the need for supplemental oxygen (Hemming 1987;
Lagos 2009; Ramilo 2014; Rodriguez 1997a). Five studies re-
ported duration of supplemental oxygen (Hemming 1987; Lagos
2009; Malley 1998; Ramilo 2014; Sáez-Llorens 2004). Five of
six studies involving children not in the ICU reported the need
for admission to the ICU (Hemming 1987; Lagos 2009; Ramilo
2014; Rodriguez 1997a; Rodriguez 1997b), and four studies also
reported the duration of stay in the ICU (Lagos 2009; Ramilo
2014; Rodriguez 1997a; Rodriguez 1997b). Two studies reported
on rehospitalisations for recurrent breathing difficulties in the long
term (Rodriguez 1997a; Rodriguez 1997b).
No studies reported on the outcomes of pulmonary function or
the occurrence of reactive airway disease in the long term.
Excluded studies
We excluded 10 study reports from the review: six were reviews
(AAP1998; Faber 2008;Givner 1999;Harkensee 2006;Hu 2010;
Wegzyn 2014); three were prophylaxis rather than treatment stud-
ies (Feltes 2011; Fernández 2010; Halsey 1997); and one study
did not randomise participants to immunoglobulin and control
groups (Helmink 2016). See Characteristics of excluded studies.
Ongoing studies
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We identified one ongoing study (NCT02442427). This study
included children aged up to three years presenting to an emer-
gency department with acute bronchitis and positive RSV antigen
test. The children were randomised to receive either a single in-
travenous dose of palivizumab or an identical saline placebo. The
primary outcome is readmission within three weeks of discharge.
Risk of bias in included studies
A summary of the ’Risk of bias’ assessment is presented in Figure
2. Risk of bias was unclear for random sequence generation in all
studies. Risk of bias was mostly low for allocation concealment,
blinding, and incomplete outcomedata. Risk of bias from selective
reporting was unclear in most studies. We assessed all studies as
at unclear or high risk of other bias due to study funding sources
and potential author conflicts of interest.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
None of the included studies adequately described the method
used to generate the randomisation sequence. Four included stud-
ies reported and used appropriate methods to conceal the alloca-
tion sequence and were rated as at low risk of bias for this do-
main (Malley 1998; Ramilo 2014; Rodriguez 1997a; Sáez-Llorens
2004). The method of concealing the allocation sequence was un-
clear in three studies (Hemming 1987; Lagos 2009; Rodriguez
1997b).
Blinding
We rated six studies as at low risk of performance bias because
appropriate steps were taken to ensure blinding of participants
and personnel (e.g. identical intervention and placebo solutions)
(Hemming 1987; Malley 1998; Ramilo 2014; Rodriguez 1997a;
Rodriguez 1997b; Sáez-Llorens 2004). We could not determine
the adequacy of blinding of participants and personnel in one
study, which we assessed as at unclear risk of bias (Lagos 2009).We
rated the risk of detection bias as low for clinical outcomes in four
studies (Malley 1998; Ramilo 2014; Rodriguez 1997a; Rodriguez
1997b). There was insufficient information in three studies to
determine the risk of detection bias, although this was unlikely
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to impact objective outcomes such as mortality or length of stay
(Hemming 1987; Lagos 2009; Sáez-Llorens 2004). We assessed
these studies as at unclear risk of bias.
Incomplete outcome data
All included studies either had no losses to follow-up or exclusions,
or had a small amount of attrition that was deemed unlikely to
bias the results. We assessed all included studies to be at low risk of
attrition bias (Hemming 1987; Lagos 2009; Malley 1998; Ramilo
2014; Rodriguez 1997a; Rodriguez 1997b; Sáez-Llorens 2004).
Selective reporting
We assessed only one study as at low risk of reporting bias, which
provided outcome data for all outcomes specified in the trial pro-
tocol (Ramilo 2014). In five studies (Lagos 2009; Malley 1998;
Rodriguez 1997a; Rodriguez 1997b; Sáez-Llorens 2004), the risk
of reporting bias was unclear because data were reported for the
outcomes specified in the methods section of the publication, but
none of the studies had an available trial protocol. It was therefore
unclear whether other outcomes were measured but not reported
based on the results. Outcomes of interest were not specified in
the methods section of one study (Hemming 1987).
Other potential sources of bias
We judged all seven included studies to be at unclear or high risk of
other potential bias. Five studies either receivedfinancial “support”
from or were “sponsored” by the intervention manufacturer to
conduct the study. In the remaining two studies, study authors or
members of the study group were employees of or had received
funding from the manufacturer.
Effects of interventions
See: Summary of findings for the main comparison
Immunoglobulins compared to placebo for treatment of
respiratory syncytial virus infection
See Summary of findings for the main comparison for the main
comparison intravenous immunoglobulin compared with placebo
for RSV infection in infants and children.
Primary outcomes
1. Mortality
Five deaths were reported among 196 children in four in-
cluded studies (Hemming 1987; Malley 1998; Rodriguez 1997a;
Sáez-Llorens 2004). We excluded data fromHemming 1987 from
analysis because the study group of the one child who died was
not reported. We found no evidence of a difference in mortal-
ity between children in the immunoglobulin and placebo groups
(risk ratio (RR) 0.87, 95% confidence interval (CI) 0.14 to
5.27; Analysis 1.1; Figure 3; very low-certainty evidence, down-
graded due to serious risk of bias and very serious imprecision).
In Rodriguez 1997a, two children in the immunoglobulin group
died; the deaths were considered by the authors to be unrelated to
the administration of immunoglobulins (one death occurred after
cardiac corrective surgery, and the other was caused by urosepsis in
a child with bronchopulmonary dysplasia). Two deaths occurred
among children in the placebo group in two studies due to pro-
gressive respiratory failure (Malley 1998), possibly complicated
by bacterial superinfection (Sáez-Llorens 2004). One child (study
group unknown) died in an accident after discharge (Hemming
1987). A breakdown of the numbers of deaths that occurred in
the included studies is presented in Table 1.
Figure 3. Forest plot of comparison: Immunoglobulins versus placebo, outcome: 1.1 Mortality.
2. Length of hospitalisation
All seven included studies reported on length of hospital stay (in
days). However, data from two studies could not be included in
themeta-analysis due tomissing variability data ormissing useable
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outcome data (median rather thanmeanwas reported) (Hemming
1987; Ramilo 2014). The length of hospital stay ranged from
4.4 to 14.5 days with immunoglobulins and 4.9 to 7.4 days with
placebo. There was no difference in length of hospitalisation (in
days) between immunoglobulins and placebo (mean difference
(MD)−0.70, 95% CI−1.83 to 0.42; Analysis 1.2, Figure 4; low-
certainty evidence, downgraded due to serious risk of bias and
serious imprecision).
Figure 4. Forest plot of comparison: Immunoglobulins versus placebo, outcome: 1.2 Length of
hospitalisation (days).
In two studies that could not be meta-analysed, the mean length
of hospital stay in the treatment and placebo groups was 3.94 days
and 3.06 days, respectively, in Hemming 1987, and the median
duration of hospitalisation was 3.05 days for the motavizumab 30
mg/kg group, 2.99 days for the motavizumab 100 mg/kg group,
and 2.88 days for the placebo group in Ramilo 2014. We con-
ducted a post hoc sensitivity analysis including the study of Ramilo
(Ramilo 2014). There was no difference in length of hospitalisa-
tion between immunoglobulins and placebo (MD −0.33, 95%
CI −1.17 to 0.51).
3. Adverse events
All seven included studies reported on adverse events. Five stud-
ies provided data on the number of children who experienced
one or more adverse events of any severity or seriousness (Lagos
2009;Malley 1998; Ramilo 2014; Rodriguez 1997a; Sáez-Llorens
2004). Four studies provided data on the number of children who
experienced one or more adverse events considered by study inves-
tigators to be serious in nature (Lagos 2009; Malley 1998; Ramilo
2014; Sáez-Llorens 2004). Two studies did not provide data, stat-
ing only that “there were no serious adverse events associated with
RSVIG therapy” in Rodriguez 1997b and “Follow up to date has
revealed no harmful effects resulting from immunotherapy of RSV
infections” in Hemming 1987.
The numbers of children who experienced one or more adverse
events (of any severity) and the number who experienced one
or more serious adverse events is presented in Table 2. Table 2
also shows the number of children who experienced one or more
adverse events considered by the study investigators to be related
to the study drug.
There was no difference between the treatment and placebo groups
in the number of children who experienced one or more adverse
events of any severity or seriousness (RR 1.18, 95% CI 0.78 to
1.78; Analysis 1.3; Figure 5; low-certainty evidence, downgraded
due to serious risk of bias and serious imprecision). There was
moderate heterogeneity (I² = 57%) amongst trials overall for this
analysis. There was no difference between treatment and placebo
groups in the number of children who experienced one or more
adverse events judged by study investigators to be serious in nature
(RR 1.08, 95% CI 0.65 to 1.79; Analysis 1.4; Figure 6; low-
certainty evidence, downgraded due to serious risk of bias and
serious imprecision).
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Figure 5. Forest plot of comparison: Immunoglobulins versus placebo, outcome: 1.3 Adverse events.
Figure 6. Forest plot of comparison: Immunoglobulins versus placebo, outcome: 1.4 Serious adverse events.
Secondary outcomes
1. Need for mechanical ventilation
Five of six studies that involved children who did not require
mechanical ventilation at study entry reported the need for sub-
sequent mechanical ventilation (Hemming 1987; Lagos 2009;
Ramilo 2014; Rodriguez 1997a; Rodriguez 1997b). Hemming
1987 reported that “Neither group included infants who... needed
ventilatory support”. This study was therefore not included in the
meta-analysis (as per Section 16.9.3 of the Cochrane Handbook
for Systematic Reviews of Interventions) (Higgins 2011). We do not
know if there is a difference in the need for mechanical ventilation
between children who received immunoglobulins and those who
received placebo (RR 1.24, 95% CI 0.64 to 2.41; Analysis 1.5;
low-certainty evidence, downgraded due to serious risk of bias and
serious imprecision).
2. Duration of mechanical ventilation
Five included studies reported duration of ventilation (in days)
(Lagos 2009; Malley 1998; Ramilo 2014; Rodriguez 1997a;
Rodriguez 1997b). However, data from two studies could not be
included in themeta-analysis due tomissing useable outcome data
(median rather thanmean was reported, or there were no variation
data) (Lagos 2009; Ramilo 2014). It is unclear if there is a differ-
ence in duration of mechanical ventilation between immunoglob-
ulins and placebo (MD −0.22, 95% CI −2.64 to 2.21; Analysis
1.6; low-certainty evidence, downgraded due to serious risk of bias
and serious imprecision).
In the two studies excluded from themeta-analysis, themediandu-
ration of ventilation was 7.8 days for children in the motavizumab
30mg/kg group and 4.6 days for children in themotavizumab 100
mg/kg group; no child in the placebo group required mechanical
ventilation (Ramilo 2014). In Lagos 2009, one child in the mo-
tavizumab 30 mg/kg group required mechanical ventilation for a
duration of 16 days. The mean duration of ventilation was five
days for two children in the placebo group.
3. Need for supplemental oxygen
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Four of five studies that included children who did not require
intubation, mechanical ventilation, or supplemental oxygen at
study entry reported the need for subsequent supplemental oxygen
(Hemming 1987; Lagos 2009; Ramilo 2014; Rodriguez 1997a).
Of these studies, two did not provide data but reported that “No
significant differences were observed between the intravenous im-
munoglobulin (IVIG)-treated and the placebo-treated groups in
the following: supplemental O requirements...” in Hemming
1987 and “no differences between the respiratory syncytial virus
immune globulin (RSVIG) and placebo groups were observed
in... supplemental oxygen” in Rodriguez 1997a. We found no evi-
dence of a difference in the need for supplemental oxygen between
immunoglobulins and placebo (RR 1.18, 95% CI 0.94 to 1.49;
Analysis 1.7; low-certainty evidence, downgraded due to serious
risk of bias and serious imprecision).
4. Duration of supplemental oxygen
Five studies reported duration of supplemental oxygen (in days)
(Hemming 1987; Lagos 2009; Malley 1998; Ramilo 2014;
Sáez-Llorens 2004). However, two of these studies were excluded
from the meta-analysis due to missing useable outcome data
(Hemming 1987; Ramilo 2014). We found no evidence of a dif-
ference in duration of supplemental oxygen between children in
the immunoglobulin and placebo groups (MD −0.54, 95% CI
−2.26 to 1.17; Analysis 1.8; low-certainty evidence, downgraded
due to serious risk of bias and serious imprecision).
In the two studies that could not be included in the meta-anal-
ysis, the median duration of supplemental oxygen was 3.0 days
for the motavizumab 30 mg/kg and 100 mg/kg groups and the
placebo group (Ramilo 2014), and the Hemming 1987 investi-
gators stated that “no significant differences” were observed in
supplemental oxygen requirements between children in the intra-
venous immunoglobulin and placebo groups, but did not provide
numerical data.
5. Need for intensive care unit admission
Five studies reported the need for admission to the ICU (Hemming
1987; Lagos 2009; Ramilo 2014; Rodriguez 1997a; Rodriguez
1997b). Of these studies, one reported that “Neither group in-
cluded infants who required admission to an intensive care unit”
(Hemming 1987), therefore data from Hemming 1987 were not
included in themeta-analysis (as per Section16.9.3 of theCochrane
Handbook for Systematic Reviews of Interventions) (Higgins 2011).
There was no evidence of a difference in the need for ICU admis-
sion between children who received immunoglobulins and those
who received placebo (RR 1.22, 95% CI 0.64 to 2.32; Analysis
1.9; low-certainty evidence, downgraded due to serious risk of bias
and serious imprecision).
6. Duration of stay in the intensive care unit
Four studies reported duration of stay (in days) in the ICU (Lagos
2009; Ramilo 2014; Rodriguez 1997a; Rodriguez 1997b). How-
ever, two studies could not be included in themeta-analysis due to
missing useable outcome data (Lagos 2009; Ramilo 2014). There
was no evidence of a difference in duration of stay in the ICU be-
tween children in the immunoglobulin and placebo groups (MD
−2.13, 95% CI −4.55 to 0.30; Analysis 1.10; low-certainty evi-
dence, downgraded due to serious risk of bias and serious impre-
cision).
In the two studies excluded from the meta-analysis, the median
duration of stay in the ICU was 10 days for the motavizumab
30 mg/kg group, 5 days for the motavizumab 100 mg/kg group,
with no ICU admissions amongst children in the placebo group
(Ramilo 2014). In Hemming 1987, one child in themotavizumab
group stayed in the ICU for 16 days; the mean duration of stay
amongst children in the placebo group was five days.
7. Pulmonary function
None of the included studies reported pulmonary function or
spirometry data.
8. Rehospitalisation for recurrent breathing difficulties in the
long term
Two studies reported readmissions during the subsequent respira-
tory seasons (Rodriguez 1997a; Rodriguez 1997b). In one study,
three (of 26) children in the RSV immunoglobulin group were
hospitalised for LRTI during the subsequent respiratory season
(all three LRTI hospitalisations were due to RSV), and three (of
26) children in the placebo group were hospitalised for LRTI dur-
ing the subsequent respiratory infections season (two were due to
RSV) (Rodriguez 1997b). In the second study, five (of 48) children
in the RSV immunoglobulin group were hospitalised for LRTI
during the subsequent respiratory infections season (three were
due to RSV), and six (of 50) children from the placebo group were
hospitalised for LRTI during the subsequent respiratory infections
season (three were due to RSV) (Rodriguez 1997a).
9. The occurrence of reactive airway disease in the long term
None of the included studies reported the occurrence of reactive
airway disease in the long term. One study reported that the in-
cidence of wheezing (a symptom of reactive airway disease) was
similar between children in the motavizumab and placebo groups
in the 12 months after randomisation (Ramilo 2014).
Subgroup analyses
We planned to undertake subgroup analyses based on children’s
age, episode of RSV, type of immunoglobulin intervention, and
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existing comorbidities. These analyses were not possible due to
lack of data.
Sensitivity analysis
We planned to conduct a sensitivity analysis to examine the effect
of risk of bias (fromallocation concealment) onoutcome estimates.
However, none of the included studies were judged to be at high
risk of bias for allocation concealment.
D I S C U S S I O N
Summary of main results
Weaimed to assess the effectiveness and safety of immunoglobulins
as a treatment for RSV-associated LRTIs in hospitalised infants
and young children.
We searched the literature to 6November 2018 and included seven
studies (486 children) that met the review inclusion criteria: two
studies compared palivizumab to placebo; two studies compared
motavizumab to placebo; and three studies compared high RSV
neutralising antibody titre immunoglobulin to placebo.
Very low-certainty evidence from three studies (downgraded in
the GRADE assessment for risk of bias and imprecision due to
small sample size and low event rates) meant that it is unclear
if there is a difference between immunoglobulins and placebo in
mortality (from any cause during hospitalisation or follow-up).
Wide confidence intervals around the estimate did not rule out a
null effect or potential harm from immunoglobulin treatment.
Low-certainty evidence from five studies (downgraded in the
GRADE assessment due to risk of bias and imprecision) indicated
that immunoglobulins did not make a significant difference in re-
ducing length of hospitalisation for children with RSV infection.
There was no difference in the number of children who experi-
enced one or more adverse events (of any severity or seriousness)
between the immunoglobulin and placebo groups based on evi-
dence from five studies assessed as at low certainty (downgraded
due to risk of bias and imprecision). There was no difference in the
number of children who experienced one or more adverse events
considered by study investigators to be serious in nature between
the immunoglobulin and placebo groups based on evidence from
three studies assessed as at low certainty (downgraded due to risk
of bias and imprecision).
Low-certainty evidence (downgraded in the GRADE assessment
due to risk of bias and imprecision) demonstrated that im-
munoglobulins did not make a significant difference in the need
for or duration of mechanical ventilation, the need for or duration
of supplemental oxygen, and the need for or duration of stay in
the ICU compared to placebo. We identified no studies providing
data on the effect of immunoglobulins on pulmonary function or
the occurrence of reactive airway disease in the long term.
Overall completeness and applicability of
evidence
Seven small studies (involving a total of 486 children) met the
review inclusion criteria. Uncertainty about the effect of im-
munoglobulins onmortality reflects the small sample sizes and low
event rates. For most comparisons, confidence intervals were very
wide, and we could not rule out the possibility of clinically rele-
vant differences. In some studies, outcome data were not always
reported in a way that could be analysed, for example reporting of
medians and absence of variation data.
All studies included hospitalised children with laboratory-con-
firmed RSV infection. All trials were conducted at sites in high-
income countries (USA, Chile, NewZealand, Australia), with two
studies including a site in a middle-income country (Panama).
The applicability of findings to low- and middle-income coun-
tries, where rates of mortality from RSV infection are higher, is
therefore unclear.
There was variation in the populations in the included studies
(children were “previously healthy”, were considered “high risk”
for RSV infections, or had chronic medical conditions) and in
the severity of illness at study entry (in two studies children were
mechanically ventilated or required more than 30% supplemental
oxygen). Given this variation, it is not clear if a specific group of
children (i.e. those with more severe illness) might benefit from
immunoglobulin treatment.
There was variation in the immunoglobulin preparations evalu-
ated in the studies. Four studies evaluated different doses of the
monoclonal immunoglobulins motavizumab (which is no longer
available) and palivizumab. The remaining studies evaluated the
pooled immunoglobulin respiratory syncytial virus immune glob-
ulin (RSVIG) (which was superseded by palivizumab). We were
unable to perform further investigation of the effect of the alter-
nate preparations in planned subgroup analysis due to the small
number of included studies.
We identified an ongoing trial comparing a single dose of
palivizumab with placebo in infants aged up to three months with
RSV bronchiolitis (NCT02442427). A primary outcome of this
review is readmission to either observation or hospital or paediatric
ICU during three weeks of follow-up after discharge. Recruitment
status is complete (last update posted 27 February 2018). This
study will be assessed for inclusion and results presented in a future
review update if appropriate.
The overall completeness and applicability of evidence was lim-
ited. There were few trials with small samples assessing the effects
of immunoglobulins, predominantly in high-income healthcare
settings.
Quality of the evidence
Using the GRADE methodology, which provides outcome-spe-
cific ratings of the certainty of evidence, we considered confidence
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in the estimate of effect to be low or very low for the primary
outcomes assessed in this review, due primarily to serious risk of
bias and imprecision.
For the primary outcomes of the review (mortality, length of hos-
pitalisation, and adverse events), we considered risk of bias to be
serious due to unclear random sequence generation (all studies),
allocation concealment (in some studies), and selective reporting
(all studies). Furthermore, we considered all studies to be at risk of
other bias because they were funded by parties with vested interest
in the results, and/or trial authors or members of the study group
had notable conflicts of interest.
We downgraded the quality of the evidence for the primary out-
comes of the review due to imprecision. The effect estimate for
mortality was derived from few small studies, a low event rate with
wide confidence intervals including the null effect for appreciable
harm or benefit. The evidence for length of hospitalisation and
adverse events was also imprecise owing to small sample size com-
pared to the calculated optimal information size, and wide con-
fidence intervals. Consequently, the estimates of effect that have
been presented should be considered uncertain, with further re-
search likely to change these estimates.
Potential biases in the review process
We attempted to limit bias in the review process by following the
methods described in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). However, there were several
possible limitations of this review related to the process of select-
ing studies, extracting data, and assessing risk of bias. Although
two review authors worked independently on each step, the sec-
ond review authors varied between and within steps (i.e. the re-
view authors screening the titles and abstracts of the original and
updated searches may have been different, and different review
authors acted as second reviewers for the risk of bias and data ex-
traction steps). The effect of this on the outcomes and conclusions
of the review is unclear. In addition, we did not attempt to obtain
data from studies reporting unuseable outcome data. Although the
search was thorough, it is possible that published and unpublished
studies were not identified. The impact of possible omission on
the results of the review is uncertain.
Agreements and disagreements with other
studies or reviews
We are aware of only one other systematic review that has ex-
amined immunoglobulins as a treatment for RSV infection (Hu
2010). This review included studies of any design published to
mid-2009 evaluating palivizumab in people of any age with RSV
infection.The review included one case report, four case series, and
two randomised trials (also included in this review). The primary
outcomes were progression from upper respiratory tract infection
(URTI) to lower respiratory tract infection (LRTI) and survival.
The methods of the search were provided, although the methods
of selecting, extracting, and appraising studies were not reported.
From the 7 included studies, Hu 2010 reported deaths in 3 of 25
(12%) participants with URTI receiving palivizumab and 5 of 88
(6%) participants with LRTI receiving palivizumab. The authors
concluded that larger RCTs are required before palivizumab can
be recommended as therapy for RSV.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review did not demonstrate that immunoglobulins improve
important clinical outcomes for children younger than three years
of age hospitalised with respiratory syncytial virus (RSV) infec-
tion. We found insufficient evidence of a difference between im-
munoglobulins and placebo for any review outcomes. We assessed
the evidence for the effects of immunoglobulins when used as a
treatment for RSV lower respiratory tract infection in hospitalised
infants and young children as of low or very low certainty due to
risk of bias and imprecision. We are uncertain of the effects of im-
munoglobulins on these outcomes, and the true effect may be sub-
stantially different from the effects reported in this review. All tri-
als were conducted in high-income countries, and data from pop-
ulations in which the rate of death from RSV infection is higher
are lacking. Due to the low certainty of the evidence, cautious
interpretation of the findings of this review is suggested.
Implications for research
Although there is no evidence of benefit in the studies included
in this review, further research may consider studying the benefits
and harms of immunoglobulins as a treatment for RSV in specific
subgroups of children.
Given the substantial burden of RSV infection, and the lack of
effective therapies at present, further research with newer mono-
clonal and pooled immunoglobulin preparations and in low-in-
come countries may be considered. Such studies should be rigor-
ously designed to minimise bias and assist applicability (e.g. by
documenting when in the course of the illness treatment com-
menced).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hemming 1987
Methods Study design: parallel-group RCT
Setting: children’s hospital
Duration: from recruitment to discharge variable. Follow-up 6 weeks and 1 year after
discharge
Participants Location: USA
Inclusion criteria
1. Admitted for treatment of pneumonia or bronchiolitis
2. Were likely to be hospitalised for more than 4 days
3. Weighed 10 kg or less
4. Had nasal and pharyngeal swab specimens in which RSV antigens were detected
by indirect immunofluorescence
5. Had informed consent by their parents
Exclusion criteria
1. Congenital heart disease
2. Inability to establish an intravenous line
3. Failure to obtain informed consent from at least 1 parent
4. Previously known hypersensitivity to blood products
Baseline characteristics (N = 35)
Mean age (SD), months: treatment: 4.4 (4.3); comparator: 4.4 (4.1)
Proportion male: not reported
Health status/disease severity: not reported
Interventions Treatment (N = 17): IV immunoglobulins containing high titres of RSV-neutralising
antibody (geometric mean neutralising antibody titres of approximately 1:5000) 2 g/kg
body weight administered over 12 to 24 hours
Comparator (N = 18): placebo 2 g/kg body weight administered over 12 to 24 hours
Outcomes 1. Geometric mean titres of serum RSV-neutralising antibody and total IgG levels
on day 1 following conclusion of infusion
2. Mean daily RSV titre reduction from baseline (expressed as 50% tissue culture
infective dose per 0.2 mL log10) in nasal wash specimens on day 1 to 4 following
conclusion of infusion
3. Increase or reduction from baseline in mean PO
oximetry values (mmHg) for study groups at day 1, 2, and 3 following conclusion of
infusion
4. Supplemental oxygen requirements during hospitalisation (no details)
5. Duration of hospitalisation (days)
6. Duration of clinical symptoms such as sneezing, wheezing, rhonchi, rales,
retractions, nasal discharge, or nasal obstruction (days)
Notes This study was supported by the manufacturer of the immunoglobulin used in the study
Risk of bias
24Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hemming 1987 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Participants were assigned to 1 of
2 equal-size treatment groups based on a
table of random numbers.” (p. 1883)
Comment: there was insufficient informa-
tion on the method used to generate the
randomisation sequence to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Comment: insufficient information on
how the allocation sequence was concealed
to permit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Only the study monitors (Sandoz
Inc, East Hanover, NJ) knew the contents
of the bottles of drug infused into each par-
ticipant. The codes were not broken un-
til the completion of each portion of the
study.” (p. 1883) “Lyophised human albu-
min, prepared in identical bottles and with
protein concentrations identical to that of
the IVIG, was used as the placebo drug.”
(p. 1882)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome assess-
ment was not described. There is insuffi-
cient information to permit judgement of
’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Complete 2 g/kg infusions were
not completed in three patients, two IVIG
treated and one placebo, because of prob-
lems maintaining venous access. IgG levels
rose in both of these IVIG-treated children.
.. suggesting receipt of most of the planned
dose” (p. 1883)
Comment: 35 participants were ran-
domised. The number of participants not
completing the study treatments was small
(3 of 35), and analysis was based on all
randomised participants for the outcomes
RSV-neutralising antibody titres, IgG lev-
els, and nasopharyngeal RSV infectivity
titres. For the outcome of oximetry, only
participants completing the infusion were
included in the analysis (32/35). Follow-
up was completed for 30 of the 35 children
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at 6 weeks and 1 year. The review authors
judge that attrition is unlikely to have an
important impact on the observed results
Selective reporting (reporting bias) Unclear risk Comment: outcomes were not specified in
the methods section. Only a description of
the tests carried out during hospitalisation
was provided. The reporting of outcomes
does not appear to be related towhether the
results were significant or not, as both were
presented. Also, without a trial protocol it
is unclear if other outcomes were measured
but not reported based on the nature of the
results
Other bias High risk Quote: “This research was supported by
Sandoz Pharmaceutical Corp.” (p. 1885)
(manufacturer of the IVIG used in this
study) and the Children’s Hospital Na-
tional Medical Center. This may lead to
bias in favour of the intervention group
Lagos 2009
Methods Study design: parallel-group RCT
Setting: hospital, not further described
Duration: recruitment to discharge variable. Adverse events “monitored through study
day 30”. (p. 835)
Participants Location: USA and Chile
Inclusion criteria
1. Previously healthy children aged < 2 years and a gestational age ≥ 36 weeks
2. Hospitalised < 24 hours for RSV lower respiratory tract illness
3. RSV detected in respiratory secretions within the previous 72 hours by direct
fluorescent antibody or rapid antigen detection
Exclusion criteria
1. Children that had been treated with antiviral agents for the current RSV infection
2. Medically significant underlying illness
3. Previous supplemental oxygen use or mechanical ventilation
4. Use of palivizumab or other immunoglobulin products within the past 2 months
Baseline characteristics
Mean age (range), months: treatment: 7.6 (1.0 to 21.8); comparator: 7.4 (0.6 to 22.6)
Proportion male: treatment 80%; comparator: 53%
Health status/disease severity: children described as “previously healthy” (p. 835). Lower
Respiratory Infection Score (6-point scale ranging from 0 = no respiratory infection to
5 = requiring mechanical ventilation): treatment: 2.5; comparator: 2.5
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Interventions Treatment (N = 5): single IV infusion of motavizumab at a dose of 3 mg/kg
Treatment (N = 5): single IV infusion of motavizumab at a dose of 15 mg/kg
Treatment (N = 5): single IV infusion of motavizumab at a dose of 30 mg/kg
Dose escalation occurred after ≥ 7 days of safety follow-up of the previous dose group
Comparator (N = 15): single IV infusion of 0.45% NaCl, which was identical in ap-
pearance to the motavizumab
Outcomes 1. Duration of hospitalisation (days)
2. Number of participants with > 1 instance of supplemental oxygen
3. Total duration of supplemental oxygen (days)
4. Number of participants admitted to ICU stay
5. Total duration of ICU stay (days)
6. Number of participants requiring mechanical ventilation
7. Total duration of mechanical ventilation (days)
8. Cultivatable RSV and viral RNA in nasal wash aspirates
9. RSV antigen in nasal secretions
10. Serum concentrations of motavizumab (µg/mL)
11. Adverse events and serious adverse events
Notes This study was funded by the manufacturer of the immunoglobulin used in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Participants were randomised in 1:
1 to groups...” (p. 835)
Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Quote: “Participants were randomised in 1:
1 to groups...” (p. 835)
Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “...identically appearing placebo”
(p. 835)
Comment: insufficient information to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “All virologic assays were per-
formed blind with respect to treatment as-
signment” (p. 835)
Comment: blinding occurred for the RSV
quantification outcomes (RSV quantifica-
tion by viral culture and reverse transcrip-
tase polymerase chain reaction), but blind-
ingwas not described for clinical outcomes.
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The risk of bias for the clinical outcomes is
unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “thirty one children were ran-
domised... Twenty-nine patients com-
pleted the study.” (p. 836)
Comment: 1 participant randomised to
motavizumabwas discontinued at day 0be-
cause the study drug could not be admin-
istered within the protocol-specified time.
1 child was lost to follow-up at day 8 af-
ter dosing but was included in the analysis,
so outcomes are reported for 30 of the 31
randomised participants. The small num-
ber (N = 1) and reason formissing outcome
data is unlikely to have an important im-
pact on the observed results
Selective reporting (reporting bias) Unclear risk Comment: outcome data are reported for
all outcomes specified in the methods sec-
tion of the publication. However, without
a trial protocol it is unclear whether other
outcomes were measured but not reported
based on the nature of the results
Other bias High risk Quote: “This research was funded byMed-
Immune” (p. 835) (manufacturer of mo-
tavizumab), and several authors were em-
ployees of MedImmune. This may lead to
bias in favour of the treatment group
Malley 1998
Methods Study design: parallel-group RCT
Setting: children’s hospitals
Duration: follow-up 30 days after administration of study treatments
Participants Location: USA
Inclusion criteria
1. < 24 months of age
2. RSV detected from respiratory secretions within 48 hours before randomisation
by direct fluorescent antibody, IFA, ELISA, or culture
3. Intubation and conventional positive pressure ventilation for < 24 hours before
randomisation
Exclusion criteria
1. Intubation for apnoea only and requiring < 30% fraction of inspired oxygen
2. Significant cardiac abnormalities
3. Diagnosis of immunodeficiency
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4. Extracorporeal membrane oxygenation or high-frequency ventilation
5. Receipt of systemic steroids within 3 weeks before randomisation unless
administered for the current RSV illness within 48 h before intubation
6. Use of oxygen for > 7 days in prior 3 months
Baseline characteristics (N = 35)
Median age (range), months: treatment: 3.2 (1.2 to 23.8); comparator: 1.7 (0.8 to 15.4)
Proportion male: treatment: 59%; comparator: 72%
Health status/disease severity: children required intubation and mechanical ventilation
at study entry. 3 children (18%) in the treatment group and 3 children (17) in the com-
parator group had “significant chronic medical conditions at the time of randomization”
(p. 1557). For the children in the treatment group, this included congenital anomalies in
1 child; microcephaly, developmental delay, and a seizure disorder in a second child; and
a third child was quadriplegic. For the children in the comparator group, this included
trisomy 21 in 2 children and Pierre Robin syndrome in 1 child
Interventions Treatment (N = 17): intravenous palivizumab 15 mg/kg
Comparator (N = 18): intravenous 0.9% saline
Outcomes 1. Reduction in tracheal RSV concentration from day 0 to day 1 and day 0 to day 2
2. RSV concentrations in nasal washes
3. White blood cell counts in tracheal aspirates
4. Days of hospitalisation
5. Days of mechanical ventilation
6. Total days of supplemental oxygen
7. Death
Notes This study was funded by the manufacturer of the immunoglobulin used in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: themethodused to generate the
allocation sequence is unclear. There was
insufficient information to permit judge-
ment
Allocation concealment (selection bias) Low risk Quote: “The study was centrally random-
ized in blocks of six per site.” (p. 1556)
Comment: an adequate method to conceal
the allocation sequence was likely used
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All clinical and laboratory per-
sonnel, the participants, and families were
blinded to the treatment assignment; the
pharmacist at each site was unblinded.” (p.
1556)
Comment: it is likely that participants and
caregivers were blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All clinical and laboratory per-
sonnel, the participants, and families were
blinded to the treatment assignment; the
pharmacist at each site was unblinded.” (p.
1556)
Comment: it is likely that the personnel
responsible for outcome data were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All 35 randomized children were
included in all analyses for which appropri-
ate data were available.” (p. 1557)
Comment: all randomised children had
data for clinical outcomes
Selective reporting (reporting bias) Unclear risk Comment: outcome data are reported for
all outcomes specified in the methods sec-
tion of the publication. However, without
a trial protocol it is unclear whether other
outcomes were measured but not reported
based on the nature of the results
Other bias High risk Quote: “Financial support: MedImmune,
Inc.” (p. 1555)
Comment: the trial was supported byMed-
Immune (manufacturer of MEDI-493).
This may lead to bias in favour of the in-
tervention group
Ramilo 2014
Methods Design: multicentre, parallel-group, 3-arm RCT
Setting: hospitals, not further described
Duration: 1 year from randomisation to final follow-up
Participants Location: “Northern and Southern Hemispheres”, “5 countries”. Trial registry indicates
study sites in USA, Panama, Chile, New Zealand, and Australia
Inclusion criteria
1. Previously healthy infants of ≥ 36 weeks gestational age
2. Aged ≤ 12 months
3. Hospitalised for LRTI with a documented positive RSV test
Exclusion criteria
1. Receiving antiviral treatment for the current RSV infection
2. Use of steroids within 30 days of randomisation
3. Medically significant underlying illness
4. Intubation for ventilatory support, previous supplemental oxygen use, or
mechanical ventilation at randomisation
5. Receipt of palivizumab or other immunoglobulin products during the 2 months
before randomisation
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Baseline characteristics (N = 118)
Median age (range), months: treatment: 2.0 (0.4 to 11.2) for the 30 mg/kg arm and 2.
2 (0.3 to 11.3) for the 100 mg/kg arm; comparator: 2.7 (0.5 to 10.3)
Proportion male: treatment: 51% for the 30 mg/kg arm and 51% for the 100 mg/kg
arm; comparator: 73%
Health status/disease severity: children were described as “previously healthy” (p. 703)
. Median (range) Respiratory Distress Assessment Instrument (RDAI) score (17-point
scale, with higher score indicating more severe wheezing and retractions): treatment: 6
(0 to 17) for the 30 mg/kg arm and 6 (0 to 13) for the 100 mg/kg arm; comparator: 4
(0 to 15)
Interventions Treatment (N = 39): single IV dose of motavizumab 30 mg/kg
Treatment (N = 39): single IV dose of motavizumab 100 mg/kg
Comparator (N = 40): placebo (not further described)
Outcomes 1. RSV viral load in nasal wash specimens by reverse transcriptase polymerase chain
reaction collected on days 0 to 6 (if still hospitalised), 7, 30, 90, 180
2. Duration of hospitalisation (days)
3. Supplemental oxygen use (number of study participants) and duration of use
(days)
4. Mechanical ventilation use (number of study participants) and duration of use
(days)
5. Admission to ICU (number of study participants) and duration of stay (days)
6. Adverse events
7. Wheezing episodes during 12-month follow-up
Notes This study was sponsored by the manufacturer of the immunoglobulin used in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible subjects were randomized
to 1:1:1...” (p. 704)
Comment: themethodused to generate the
allocation sequence is unclear. There is in-
sufficient information topermit judgement
Allocation concealment (selection bias) Low risk Quote: “Eligible subjects were randomized
to 1:1:1 using an interactive voice response
system to receive... The interactive voice
response system was also used for assign-
ment of patient identification number and
assignment of blinded study drug kits.” (p.
704)
Comment: an adequate method was used
to conceal the allocation sequence
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...assignment of blinded study
drug kits ...Subjects parents/guardians,
clinical site staff and protocol-associated
personnel were blinded to group assign-
ment.” (p. 704)
Comment: it is likely that participants and
care providers were blinded, although the
appearance of the interventions is not de-
scribed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Subjects parents/guardians, clini-
cal site staff and protocol-associated per-
sonnel were blinded to group assignment...
At a central laboratory, personnel who were
blinded to treatment assignment tested
nasal specimens...” (p. 704)
Comment: personnel responsible for the
virologic and clinical outcome data were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “A total of 118 subjects were ran-
domized... and 113 subjects received study
drug. One hundred and seven subjects
completed through study day 90 and 98
subjects completed through study day 360.
Similar rates of non-completion were ob-
served among subjects treated with mo-
tavizumab or placebo.” (p. 704)
Comment: 91% (107/118) of randomised
participants remained in the study at day
90, with a similar number of non-com-
pleters in the study groups. Clinical out-
come data are provided for 112 of 113
participants who received the study drug
(1 participant was found to be negative
for RSV at study day 0). Of the 112 par-
ticipants with clinical outcome data, du-
ration of hospitalisation data are available
for 111 (1 participant in the motavizumab
30 mg/kg group withdrew consent). The
review authors judge that the reasonably
small number of participants randomised
but not included in the analysis and the
similar numbers lost to follow-up in the
study groups is unlikely to have an impor-
tant impact on the observed results
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Selective reporting (reporting bias) Low risk Comment: outcome data were fully re-
ported for all outcomes specified in Clini-
calTrials.gov registry entry NCT00421304
Other bias High risk Quote: “This study was sponsored byMed-
Immune.” (p. 703)
Comment: the study was sponsored by
MedImmune (the manufacturer of mo-
tavizumab), and a number of the study in-
vestigators received funding from or were
employees of MedImmune. This may lead
to bias in favour of the intervention group
Rodriguez 1997a
Methods Design: multicentre, parallel-group RCT
Setting: children’s and university hospitals
Duration: recruitment to discharge variable. Children were followed up in the next RSV
season
Participants Location: USA
Inclusion criteria
1. High-risk infants and young children including those with severe
bronchopulmonary dysplasia, other severe lung disease, or congenital heart disease and
infants born prematurely (< 32 weeks’ gestation who were < 6 months old at the time
of enrolment)
2. Hospitalised for RSV bronchiolitis or pneumonia, or both, as defined by nasal
specimens positive for RSV antigens by immunofluorescence or ELISA
3. Aged up to 2 years
Exclusion criteria
1. Poorly controlled congestive heart failure before the RSV illness
2. Renal failure
3. Ventilator dependency before the RSV illness
4. Life expectancy of less than 6 months from study onset
5. Treatment with ribavirin before enrolment
6. Previous adverse reaction to blood products
7. Known serum immunoglobulin A deficiency or other immunodeficiency
8. Enrolment in a concurrent RSV immunoglobulin prophylaxis study
9. Patients with known cystic fibrosis, asthma, or reactive airway disease in the
absence of bronchopulmonary dysplasia
10. Patients presenting with apnoea without evidence of lower tract infection
Baseline characteristics (N = 102 (of 107 children randomised))
Mean age (SE), months: treatment: 0.55 (0.07); comparator: 0.58 (0.06)
Proportion male: treatment: 45%; comparator: 57%
Health status/disease severity: children were described as high risk for severe RSV infec-
tion.High-risk children included thosewith severe bronchopulmonary dysplasia, chronic
lung disease, congenital heart disease, or prematurity. Mean (SE) respiratory score (score
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ranges from 0 to 5, with higher scores indicating more severe disease): treatment: 3.4 (0.
2); comparator: 3.1 (0.1). Proportion with Lower Respiratory Tract Infection Score 5
(score ranges from 0 to 5, with 5 indicating respiratory failure): treatment: 31%; com-
parator: 18%
Interventions Treatment (N = 54): 30 mL/kg RSVIG (1.5 mg/kg IVIG) given intravenously over 12
hours
Comparator (N = 54): 0.15 mg/kg of albumin given intravenously over 12 hours
Outcomes Primary
1. Duration of hospital stay (days)
Secondary
1. Duration of ICU stay (days)
2. Duration of mechanical ventilation (days)
3. Duration of oxygen therapy (days)
4. Use of ribavirin
5. Use of supplemental oxygen
Notes Some members of the study group were employees of the manufacturer of the im-
munoglobulin used in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: themethodused to generate the
allocation sequence is unclear. There was
insufficient information to permit judge-
ment
Allocation concealment (selection bias) Low risk Quote: “Each year of the study, MPHBL
coded vials by one of six letters... Only
MPHBL and the Data and Safety Moni-
toring Board member knew the contents of
the vials until the study code was broken.
.. Each centre received from MedImmune
Inc a randomization schedule that ensured
that each center enrolled nearly equal num-
bers of RSVIG and placebo patients by bal-
ancing randomisation in blocks of six. Pa-
tients who fit the inclusion criteria were as-
signed to the next lettered vial specified in
the randomizations scheme for each centre.
” (p. 456)
Comment: an adequate method was likely
used to conceal the allocation sequence
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Bottles containing respiratory syn-
cytial virus immunoglobulin or placebo
were codedby theMPHBL so that contents
were unknown to the investigators, spon-
sor, and study participants... A 0.5% solu-
tion of albumin bottled identically to the
RSVIG was used as the placebo solution.”
(p. 456)
Comment: it is likely that participants and
care providers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Bottles containing respiratory syn-
cytial virus immunoglobulin or placebo
were coded by the MPHBL so that con-
tents were unknown to the investigators,
sponsor, and study participants... A 0.5%
solution of albumin bottled identically to
the RSVIG was used as the placebo solu-
tion... Attending physicians not associated
with the study were responsible for routine
treatment... Furthermore, they determined
when to administer supplemental oxygen,
the level of oxygen therapy, or the need for
mechanical ventilation. Likewise, the deci-
sion for hospital discharge was made by the
attending physicians.” (p. 456)
Comment: it is likely that the personnel
responsible for outcome data were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Fifty four patients were random-
ized to receive RSVIG, and 53 were ran-
domized to receive placebo. Three children
in the RSVIG group and 2 in the placebo
group received less than 75%of the ordered
dose and those were not evaluable for effi-
cacy.” (p. 457)
Comment: the review authors judge that
owing to the small number of participants
not completing study treatments and ex-
cluded from the analysis, the similar num-
bers in each study group, and for reasons
unlikely to be related to the outcomes, this
is unlikely to have an important impact on
the observed results
Selective reporting (reporting bias) Unclear risk Comment: outcome data are reported for
all outcomes specified in the methods sec-
tion of the publication. However, without
a trial protocol it is unclear whether other
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outcomes were measured but not reported
based on the nature of the results
Other bias Unclear risk Quote: “This work was supported by grant
H5 MO1RR0069, General Clinical Re-
search Centers program, from theNational
Institutes of Health (University of Col-
orado).” (p. 460)
Comment: a number of members of the
RSVIG Study Group were employees of
MedImmune (manufacturer of RSVIG).
This may lead to bias in favour of the in-
tervention group
Rodriguez 1997b
Methods Design: multicentre, parallel-group RCT
Setting: children’s and university hospitals
Duration: recruitment to discharge variable. Follow-up 8 weeks after discharge and
during the following respiratory season
Participants Location: USA
Inclusion criteria
1. Previously healthy children ≤ 2 years of age
2. Hospitalised for bronchiolitis or pneumonia, or both, who are positive for RSV
antigen by immunofluorescence or ELISA
3. Had acute lower respiratory symptoms less that 4 days’ duration
4. Had a respiratory score ≥ 2.5
Exclusion criteria
1. Known or suspected cardiopulmonary disease
2. Premature birth (< 32 weeks)
3. Immunodeficiency disease
4. Renal failure
5. Previous reaction to blood products or having received blood products in the
preceding 60 days
6. Established diagnosis of reactive airways disease
7. Apnoea without evidence of lower tract infection
8. Inability to establish intravenous line (4 attempts maximum)
Baseline characteristics (N = 101)
Mean age (SE), months: treatment: 0.20 (0.03); comparator: 0.19 (0.03)
Proportion male: treatment 48%; comparator 50%
Health status/disease severity: children were described as “previously healthy” (p. 938)
. Mean (SE) Respiratory score (score ranges from 0 to 5, with higher scores indicating
more severe disease): treatment: 3.69 (0.13); comparator: 3.77 (0.13). Proportion with
Lower Respiratory Tract Infection Score 5 (score ranges from 0 to 5, with 5 indicating
respiratory failure): treatment: 28%; comparator: 33%
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Interventions Treatment (N = 47): 30 mL/kg (1500 mg/kg) infusion of RSVIG
Comparator (N = 54): 30 mL/kg (1500 mg/kg) infusion of albumin placebo
Outcomes Primary
1. Duration of hospitalisation (days)
Secondary
1. Duration of stay in the ICU (days)
2. Duration of mechanical ventilation (days)
3. Duration of oxygen therapy (days)
4. Use of ribavirin
5. Supplemental oxygen
Other
1. Respiratory score (used as an inclusion criterion and to conduct stratified analyses
in the study)
2. Lower Respiratory Infection score (clinical investigator’s assessment of
participants)
3. Analogue scale of disease severity (visual disease severity scoring system)
Notes This study was supported by the manufacturer of the immunoglobulin used in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: themethodused to generate the
allocation sequence is unclear. There was
insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Quote: “Bottles containing RSVIG or
placebo were coded by the Massachusetts
Public Health Biological Laboratories so
that controls were unknown to investiga-
tors, sponsor and study participants.” (p.
938)
Comment: there was insufficient informa-
tion to permit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “A one half percent (0.5%) solu-
tion of albumin bottled identically to the
RSBIG was utilized as the placebo control
solution.” (p. 938)
Comment: it is likely that participants and
care providers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Bottles containing respiratory syn-
cytial virus immunoglobulin or placebo
were coded by the Massachusetts Public
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Health Biological Laboratories so that con-
tents were unknown to the investigators,
sponsor, and study participants. ...A 0.5%
solution of albumin bottled identically to
the RSVIG was used as the placebo so-
lution... Attending physicians determined
whether and when supplemental oxygen or
mechanical ventilation was required. The
decision for hospital discharge was also
made by the attendingphysicians.” (p. 938)
Comment: it is likely that the personnel
responsible for the primary and secondary
outcome data were blinded. It is unclear
who evaluated participants by the analogue
scale, LRI, and respiratory score and if they
were blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One hundred one patients were
enrolled in the trial, 47 in the RSVIG
group and 54 in the placebo group. Forty-
six RSVIG (98%) and 52 placebo recipi-
ents (96%) could be evaluated. Excluded
from the evaluation were 1 infant in the
RSVIG group who received less than 75%
of the infusion, 1placebo recipientwhohad
an admission respiratory score < 2.5, and 1
placebo patient on whom we were unable
to start an intravenous infusion.” (p. 939)
Comment: the review authors judge that
owing to the small number of participants
not completing study treatments and ex-
cluded from the analysis, the similar num-
bers in each study group, and for reasons
unlikely to be related to the outcomes, this
is unlikely to have an important impact on
the observed results
Selective reporting (reporting bias) Unclear risk Comment: outcome data are reported for
all outcomes specified in the methods sec-
tion of the publication. However, without
a trial protocol it is unclear whether other
outcomes were measured but not reported
based on the nature of the results
Other bias High risk Quote: “This study was supported by
MedImmune, Inc. and by Grant H5
MO1RR0069, General Clinical Research
Centers Program National Institutes of
Health (University of Colorado).” (p. 941)
Comment: the study is supported in part by
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MedImmune, and a number of members
of the RSVIG Study Group are employees
of MedImmune (manufacturer of RSVIG)
. This may lead to bias in favour of the
intervention group
Sáez-Llorens 2004
Methods Design: multicentre, parallel-group RCT
Setting: hospitals, not further described
Study duration: follow-up for 30 days after study drug administration and during the
following RSV season
Participants Location: USA and Panama
Inclusion criteria
1. ≤ 24 months of age at the time of randomisation
2. Hospitalised within 72 hours before randomisation into the study for RSV
bronchiolitis or pneumonia, or both, as documented by antigen detection in
nasopharyngeal or lower respiratory tract secretions collected within 48 hours before
randomisation
3. Required > 30% supplemental oxygen
Exclusion criteria
1. Therapy with ribavirin for the current illness before randomisation
2. Significant underlying chronic or acute disease other than the RSV infection (e.g.
bronchopulmonary dysplasia)
3. Known renal, hepatic, haematologic, neurologic, or immunologic disorder
4. Requirement for supplemental oxygen in the past 6 months (brief oxygen use at
birth, oxygen use of < 1 week to treat an intercurrent illness, or need for oxygen or
mechanical ventilation during the current RSV infection was allowed)
5. Mechanical ventilation at any time before the onset of the current RSV infection
6. Congenital heart disease (except corrected patent ductus arteriosus with no other
congenital heart disease)
7. Previous reaction to immunoglobulin, blood products, or other foreign proteins
8. Previous treatment with any immunoglobulin product within the past 2 months
9. Therapy with any other investigational agent currently or within the past 3
months
10. Previous or current participation in any investigational study of vaccines or
immunotherapeutic agents for RSV
Baseline characteristics (N = 59)
Mean age (SE), months: treatment: 1.5 (0.4) for palivizumab 5 mg/kg arm and 5.2 (0.
9) for palivizumab 15 mg/kg arm; comparator: 2.9 (0.7) for the group compared to
palivizumab 5 mg/kg arm and 4.2 (0.8) for the group compared to palivizumab 15 mg/
kg arm
Proportionmale: treatment: 75% for palivizumab 5mg/kg arm and 59% for palivizumab
15 mg/kg arm; comparator: 13% for the group compared to palivizumab 5 mg/kg arm
and 48% for the group compared to the palivizumab 15 mg/kg arm
Health status/disease severity: children described as “previously healthy” (p. 707). Chil-
dren required > 30% supplemental oxygen at study entry. Proportion with Lower Res-
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Sáez-Llorens 2004 (Continued)
piratory Infection score ≥ 3 (score ranges from 0 to 5, with 0 indicating no respiratory
illness, 3 indicating moderate lower respiratory infection, and 5 indicating the need for
mechanical ventilation): treatment: 100% for palivizumab 5 mg/kg arm and 36% for
palivizumab 15 mg/kg arm; comparator: 88% for the group compared to palivizumab
5 mg/kg arm and 33% for the group compared to palivizumab 15 mg/kg arm
Interventions Treatment (N = 8): 5 mg/kg intravenous palivizumab
Treatment (N = 22): 15 mg/kg intravenous palivizumab. The dose of palivizumab was
increased to 15 mg/kg after the first 12 children receiving the 5 mg/kg dose had been
followed for at least 5 days after treatment without the occurrence of dose-limiting
toxicity or serious adverse event
Comparator (N = 29): placebo (0.9% normal saline)
Outcomes 1. Adverse events
2. Serum palivizumab concentrations (before administration of study drug, 60
minutes after infusion, and 2, 5, 14, and 30 days after infusion) (for intervention group
only and comparing participants receiving doses of 5 mg/kg and 15 mg/kg
palivizumab)
3. Duration of hospitalisation (days)
4. Hospital days of supplemental oxygen therapy
5. RSV hospitalisation days with LRI score ≥ 3
Notes Members of the study group were employees of themanufacturer of the immunoglobulin
used in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were randomized
centrally 1:1...” (p. 707)
Comment: although randomisation ap-
peared to be independent of study investi-
gators, the way the sequence was generated
was not described. There was insufficient
information to permit judgement
Allocation concealment (selection bias) Low risk Quote: “Eligible patients were random-
ized 1:1 centrally by the investigator call-
ing Pharmaceutical Products Development
Inc. and obtaining the next available pa-
tient identification number with specified
study drug.” (p. 707)
Comment: an adequate method was likely
used to conceal the allocation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study drug was dispensed
from the pharmacy in a blinded manner; i.
e., the study drug assignment was not on
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Sáez-Llorens 2004 (Continued)
the label” (p. 708)
Comment: it is likely that participants and
care providers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Adverse events considered by the
blinded investigator to be possibly related.
..” (p. 710)
Comment: the study states that adverse
events were classified by a blind investiga-
tor, however it is unclear whether clinical
outcomeswere reported by blind clinicians,
and the risk of detection bias is unclear for
these outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “A total of 60 children were ran-
domized and 59 received the study drug.
One child was randomized but did not re-
ceive any study drug because of a protocol
violation: this patient was not included in
any of the analyses... Overall 56 patients
(95%) were followed through 30 days af-
ter study drug administration.One placebo
patient died during RSV hospitalisation
and 2 patients, one placebo and the other
15 mg/kg palivizumab were lost to follow-
up during the 30 day post treatment pe-
riod” (p. 709)
Comment: only 1 randomised participant
was not included in the analysis for adverse
events and clinical outcomes, and this was
due to a protocol violation. Attrition in this
study is unlikely to have an important im-
pact on the observed results
Selective reporting (reporting bias) Unclear risk Comment: outcome data are reported for
all outcomes specified in the methods sec-
tion of the publication. However, without
a trial protocol it is unclear whether other
outcomes were measured but not reported
based on the nature of the results
Other bias Unclear risk Quote: “We thank Barbara Shepherd, PhD
of MedImmune, Inc. for assistance with
preparation of the manuscript” (p. 712)
Comment: the paper acknowledges an em-
ployee of MedImmune (palivizumab man-
ufacturer) for assistance with preparation of
the manuscript. A member of the MEDI-
493 Study Group is an employee of Med-
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Sáez-Llorens 2004 (Continued)
Immune. This may lead to bias in favour
of the intervention group
ELISA: enzyme-linked immunosorbent assay
ICU: intensive care unit
IFA: immunofluorescence assay
IgG: immunoglobulin G
IV: intravenous
IVIG: intravenous immunoglobulins
LRI: lower respiratory infection
LRTI: lower respiratory tract infection
N: number (of people)
NaCl: normal saline
PO : partial pressure of oxygen
RCT: randomised controlled trial
RNA: ribonucleic acid
RSV: respiratory syncytial virus
RSVIG: respiratory syncytial virus immunoglobulins
SD: standard deviation
SE: standard error
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AAP 1998 Not an RCT (review)
Faber 2008 Not an RCT (review)
Feltes 2011 This study looked at prophylaxis, not treatment.
Fernández 2010 This study looked at prophylaxis, not treatment.
Givner 1999 Not an RCT (review)
Halsey 1997 This study looked at prophylaxis, not treatment.
Harkensee 2006 Not an RCT (review)
Helmink 2016 This study did not randomise participants to palivizumab or control
Hu 2010 Not an RCT (review)
Wegzyn 2014 Not an RCT (review)
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RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT02442427
Trial name or title Palivizumab therapy for RSV-bronchiolitis
Methods Randomised placebo-controlled trial
Participants Infants 3 years of age or younger presenting to an emergency department with acute bronchitis and positive
RSV rapid antigen test
Interventions Single-dose intravenous palivizumab versus saline placebo comparator
Outcomes Readmission during 3-week follow-up after discharge
Starting date September 2014
Contact information Information provided by: Hamad Medical Corporation
Notes Sponsor: Hamad Medical Corporation
RSV: respiratory syncytial virus
43Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Immunoglobulins versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (any cause during
hospitalisation or follow-up)
3 196 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.14, 5.27]
2 Length of hospitalisation (days) 5 324 Mean Difference (IV, Random, 95% CI) -0.70 [-1.83, 0.42]
3 Adverse events of any severity or
seriousness
5 340 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.78, 1.78]
4 Serious adverse events 4 238 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.65, 1.79]
5 Need for mechanical ventilation 4 341 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.64, 2.41]
6 Duration of mechanical
ventilation
3 100 Mean Difference (IV, Random, 95% CI) -0.22 [-2.64, 2.21]
7 Need for supplemental oxygen 2 142 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.94, 1.49]
8 Duration of supplemental
oxygen
3 115 Mean Difference (IV, Random, 95% CI) -0.54 [-2.26, 1.17]
9 Need for ICU admission 4 341 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.64, 2.32]
10 Duration of stay in the ICU 2 107 Mean Difference (IV, Random, 95% CI) -2.13 [-4.55, 0.30]
Analysis 1.1. Comparison 1 Immunoglobulins versus placebo, Outcome 1 Mortality (any cause during
hospitalisation or follow-up).
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 1 Mortality (any cause during hospitalisation or follow-up)
Study or subgroup Ig Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
S ez-Llorens 2004 0/30 1/29 32.1 % 0.32 [ 0.01, 7.61 ]
Malley 1998 0/17 1/18 32.6 % 0.35 [ 0.02, 8.09 ]
Rodriguez 1997a 2/51 0/51 35.3 % 5.00 [ 0.25, 101.63 ]
Total (95% CI) 98 98 100.0 % 0.87 [ 0.14, 5.27 ]
Total events: 2 (Ig), 2 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.02, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ig Favours placebo
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Analysis 1.2. Comparison 1 Immunoglobulins versus placebo, Outcome 2 Length of hospitalisation (days).
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 2 Length of hospitalisation (days)
Study or subgroup Ig Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Malley 1998 17 14.5 (8.7) 18 11.5 (6.4) 4.9 % 3.00 [ -2.08, 8.08 ]
Lagos 2009 15 4.9 (5.2) 15 6.8 (7.4) 6.0 % -1.90 [ -6.48, 2.68 ]
Rodriguez 1997a 51 8.4 (6.9) 51 8.8 (7.1) 17.1 % -0.40 [ -3.12, 2.32 ]
S ez-Llorens 2004 30 4.4 (4.5) 29 5.4 (5.6) 18.8 % -1.00 [ -3.60, 1.60 ]
Rodriguez 1997b 46 4.6 (2.7) 52 5.5 (4.9) 53.1 % -0.90 [ -2.44, 0.64 ]
Total (95% CI) 159 165 100.0 % -0.70 [ -1.83, 0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.46, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Ig Favours placebo
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Analysis 1.3. Comparison 1 Immunoglobulins versus placebo, Outcome 3 Adverse events of any severity or
seriousness.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 3 Adverse events of any severity or seriousness
Study or subgroup Ig Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lagos 2009 11/16 6/15 18.0 % 1.72 [ 0.85, 3.47 ]
Malley 1998 7/17 6/18 14.1 % 1.24 [ 0.52, 2.94 ]
Ramilo 2014 60/76 33/37 36.3 % 0.89 [ 0.75, 1.04 ]
Rodriguez 1997a 16/51 10/51 18.4 % 1.60 [ 0.80, 3.18 ]
S ez-Llorens 2004 7/30 7/29 13.2 % 0.97 [ 0.39, 2.41 ]
Total (95% CI) 190 150 100.0 % 1.18 [ 0.78, 1.78 ]
Total events: 101 (Ig), 62 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 9.27, df = 4 (P = 0.05); I2 =57%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ig Favours placebo
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Analysis 1.4. Comparison 1 Immunoglobulins versus placebo, Outcome 4 Serious adverse events.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 4 Serious adverse events
Study or subgroup Ig Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lagos 2009 1/16 1/15 3.5 % 0.94 [ 0.06, 13.68 ]
Malley 1998 7/17 6/18 33.8 % 1.24 [ 0.52, 2.94 ]
Ramilo 2014 13/76 6/37 32.4 % 1.05 [ 0.44, 2.55 ]
S ez-Llorens 2004 7/30 7/29 30.3 % 0.97 [ 0.39, 2.41 ]
Total (95% CI) 139 99 100.0 % 1.08 [ 0.65, 1.79 ]
Total events: 28 (Ig), 20 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ig Favours placebo
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Analysis 1.5. Comparison 1 Immunoglobulins versus placebo, Outcome 5 Need for mechanical ventilation.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 5 Need for mechanical ventilation
Study or subgroup Ig Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lagos 2009 1/15 2/15 7.5 % 0.50 [ 0.05, 4.94 ]
Ramilo 2014 4/74 0/37 4.9 % 4.56 [ 0.25, 82.51 ]
Rodriguez 1997a 21/51 11/51 42.5 % 1.91 [ 1.03, 3.54 ]
Rodriguez 1997b 14/46 19/52 45.1 % 0.83 [ 0.47, 1.47 ]
Total (95% CI) 186 155 100.0 % 1.24 [ 0.64, 2.41 ]
Total events: 40 (Ig), 32 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 5.19, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ig Favours placebo
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Analysis 1.6. Comparison 1 Immunoglobulins versus placebo, Outcome 6 Duration of mechanical
ventilation.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 6 Duration of mechanical ventilation
Study or subgroup Ig Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Malley 1998 17 8.8 (9.5) 18 6.2 (6.4) 20.1 % 2.60 [ -2.80, 8.00 ]
Rodriguez 1997a 21 9.7 (7.8) 11 9.9 (6.7) 21.9 % -0.20 [ -5.38, 4.98 ]
Rodriguez 1997b 14 4.3 (2.4) 19 5.5 (6.5) 58.0 % -1.20 [ -4.38, 1.98 ]
Total (95% CI) 52 48 100.0 % -0.22 [ -2.64, 2.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Ig Favours placebo
Analysis 1.7. Comparison 1 Immunoglobulins versus placebo, Outcome 7 Need for supplemental oxygen.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 7 Need for supplemental oxygen
Study or subgroup Ig Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lagos 2009 11/15 10/15 24.1 % 1.10 [ 0.69, 1.76 ]
Ramilo 2014 59/75 24/37 75.9 % 1.21 [ 0.93, 1.58 ]
Total (95% CI) 90 52 100.0 % 1.18 [ 0.94, 1.49 ]
Total events: 70 (Ig), 34 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ig Favours placebo
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Analysis 1.8. Comparison 1 Immunoglobulins versus placebo, Outcome 8 Duration of supplemental oxygen.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 8 Duration of supplemental oxygen
Study or subgroup Ig Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lagos 2009 11 4 (4.9) 10 4.9 (3) 24.8 % -0.90 [ -4.34, 2.54 ]
Malley 1998 17 12.3 (9.5) 18 9.5 (6.8) 9.7 % 2.80 [ -2.70, 8.30 ]
S ez-Llorens 2004 30 3.3 (3.5) 29 4.2 (4.7) 65.4 % -0.90 [ -3.02, 1.22 ]
Total (95% CI) 58 57 100.0 % -0.54 [ -2.26, 1.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.57, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Ig Favours placebo
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Analysis 1.9. Comparison 1 Immunoglobulins versus placebo, Outcome 9 Need for ICU admission.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 9 Need for ICU admission
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lagos 2009 1/15 2/15 6.9 % 0.50 [ 0.05, 4.94 ]
Ramilo 2014 6/74 0/37 4.6 % 6.59 [ 0.38, 113.85 ]
Rodriguez 1997a 31/51 18/51 42.5 % 1.72 [ 1.12, 2.65 ]
Rodriguez 1997b 25/46 33/52 46.0 % 0.86 [ 0.61, 1.20 ]
Total (95% CI) 186 155 100.0 % 1.22 [ 0.64, 2.32 ]
Total events: 63 (Experimental), 53 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 8.63, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ig Favours placebo
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Analysis 1.10. Comparison 1 Immunoglobulins versus placebo, Outcome 10 Duration of stay in the ICU.
Review: Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Comparison: 1 Immunoglobulins versus placebo
Outcome: 10 Duration of stay in the ICU
Study or subgroup IG Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rodriguez 1997a 31 9.77 (9.25) 18 10.27 (7.67) 25.4 % -0.50 [ -5.31, 4.31 ]
Rodriguez 1997b 25 3.92 (2.9) 33 6.6 (7.52) 74.6 % -2.68 [ -5.49, 0.13 ]
Total (95% CI) 56 51 100.0 % -2.13 [ -4.55, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours IG Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Mortality from any cause during hospitalisation or follow-up
Study Number of deaths in the
immunoglobulin group
Immunoglobulin group
total
Number of deaths in the
placebo group
Placebo group total
Hemming 1987 1 death (study group unknown)
Malley 1998 0 17 1 18
Rodriguez 1997a 2 51 0 50
Sáez-Llorens 2004 0 30 1 29
Table 2. Adverse events
Study Number of children/total
number in group (%) expe-
riencing ≥ 1 adverse event
Number of children/total
number in group (%) ex-
periencing ≥ 1 adverse
event judged by study in-
vestigators to be serious in
nature
Number of participants/to-
tal number in group (%)
experiencing ≥ 1 adverse
event judged by study in-
vestigators to be related to
study drug
Narrative results pro-
vided by the study in-
vestigators
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Table 2. Adverse events (Continued)
Im-
munoglobu-
lin
Placebo Immunoglob-
ulin
Placebo Immunoglobu-
lin
Placebo
Lagos 2009 11/16 (69) 6/15 (40) 1/16 (6) 1/15 (7) 0 0 “The frequency of AEs
was similar between
the combined mo-
tavizumab groups and
the placebo group” (p.
836)
Ramilo 2014 60/76 (79) 33/37 (89) 13/76 (17) 6/37 (16) 6/76 (8) 4/37 (11) “The incidence rates of
AEs and SAEs
were similar for the 3
groups” (p. 706)
Rodriguez
1997a
16/51 (31) 10/51 (20) NA NA 16 of 22 adverse events
among the 16 immunoglobu-
lin participants experiencing
≥ 1 adverse event and 8 of
11 adverse events among 10
placebo participants experi-
encing≥ 1 adverse event were
judged to be related to study
drug
“No significant differ-
ences in adverse events
were reported
in the RSVIG group..
. when compared with
the control group” (p.
454)
Malley 1998 NA NA 7/17 (41) 6/18 (33) 0 0 “The percent-
age of children report-
ing adverse events and
the total number of ad-
verse events were simi-
lar in the placebo and
MEDI0493 groups”
(p. 1559)
Sáez-Llorens
2004
NA NA 7/30 (23) 7/29 (24) 1/30 (3) 3/30 (10) “The incidence of indi-
vidual adverse
eventswas balanced be-
tween the placebo and
palivizumab treatment
groups for each dose”
(p. 710)
AE: adverse event, NA: not available, RSVIG: respiratory syncytial virus immunoglobulin, SAE: serious adverse event
53Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. MEDLINE and CENTRAL search strategy
MEDLINE (Ovid)
1 exp Bronchiolitis/
2 bronchiolit*.tw.
3 exp Pneumonia/
4 (pneumon* or bronchopneumon* or pleuropneumon*).tw.
5 Respiratory Tract Infections/
6 lower respiratory infection*.tw.
7 (lower respiratory tract infection* or lrti).tw.
8 respiratory syncytial viruses/ or respiratory syncytial virus, human/
9 Respiratory Syncytial Virus Infections/
10 (respiratory syncytial virus* or rsv).tw.
11 or/1-10
12 exp Immunoglobulins/
13 immunoglobulin*.tw,nm.
14 (immune adj2 globulin*).tw.
15 rsv-igiv.tw,nm.
16 respigam.tw,nm.
17 palivizumab.tw,nm.
18 synagis.tw,nm.
19 or/12-18
20 11 and 19
Appendix 2. Embase (Elsevier) search strategy
#19 #15 AND #18
#18 #16 OR #17
#17 random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR (((singl* OR doubl*) NEXT/1 blind*):ab,ti)
#16 ’randomised controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#15 #9 AND #14
#14 #10 OR #11 OR #12 OR #13
#13 ’rsv-igiv’:ab,ti OR respigam:ab,ti OR palivizumab:ab,ti OR synagis:ab,ti
#12 (immune NEAR/2 globulin*):ab,ti
#11 immunoglobulin*:ab,ti
#10 ’immunoglobulin’/exp
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#8 ’respiratory syncytial virus’:ab,ti OR ’respiratory syncytial viruses’:ab,ti OR rsv:ab,ti
#7 ’respiratory syncytial pneumovirus’/de OR ’respiratory syncytial virus infection’/de
#6 ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR ’lower respiratory infection’:ab,ti OR ’lower
respiratory infections’:ab,ti OR lrti:ab,ti
#5 ’respiratory tract infection’/de OR ’lower respiratory tract infection’/exp
#4 pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti
#3 ’pneumonia’/exp
#2 bronchiolit*:ab,ti
#1 ’bronchiolitis’/exp
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Appendix 3. CINAHL (EBSCO) search strategy
S26 S16 and S25 59
S25 S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24
S24 (MH “Quantitative Studies”)
S23 (MH “Placebos”)
S22 TI placebo* OR AB placebo*
S21 TI random* OR AB random*
S20 TI ((singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*)) OR AB ((singl* or doubl* or tripl* or trebl*)W1 (blind* or mask*))
S19 TI clinic* trial* OR AB clinic* trial*
S18 PT clinical trial
S17 (MH “Clinical Trials+”)
S16 S10 and S15
S15 S11 or S12 or S13 or S14
S14 TI (rsv-igiv or respigam or palivizumab or synagis) OR AB (rsv-igiv or respigam or palivizumab or synagis)
S13 TI immune N2 globulin* OR AB immune N2 globulin*
S12 TI immunoglobulin* OR AB immunoglobulin*
S11 (MH “Immunoglobulins+”)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 16135
S9 TI (respiratory syncytial virus* or rsv) OR AB (respiratory syncytial virus* or rsv)
S8 (MH “Respiratory Syncytial Virus Infections”)
S7 (MH “Respiratory Syncytial Viruses”)
S6 TI (lower respiratory tract infection* or lower respiratory infection* or lrti) OR AB (lower respiratory tract infection* or lower
respiratory infection* or lrti)
S5 (MH “Respiratory Tract Infections”)
S4 TI pneumon* OR AB pneumon*
S3 (MH “Pneumonia+”)
S2 TI bronchiolit* OR AB bronchiolit*
S1 (MH “Bronchiolitis+”)
Appendix 4. Web of Science (Clarivate Analytics) search strategy
TOPIC: ((bronchiolit* or pneumon* or bronchopneumon* or pleuropneumon* or “lower respiratory tract infection*” or “lower
respiratory infection*” or lrti or rsv or “respiratory syncytial virus” or “respiratory syncytial viruses”)) ANDTOPIC: ((immunoglobulin*
or “immune globulin” or “rsv-igiv” or respigam or palivizumab or synagis))
Refined by: TOPIC: ((random* or placebo* or “clinic* trial*” or “singl* blind*” or “doubl* blind*”))
Timespan: All years. Indexes: SCI-EXPANDED, CPCI-S.
C O N T R I B U T I O N S O F A U T H O R S
Sharon L Sanders: screened searches, extracted data, assessed risk of bias, analysed results, and drafted the final review
Sushil Agwan: extracted data, verified data entry, drafted sections of the final review, and reviewed draft
Mohamed Hassan: extracted data, verified data entry, drafted sections of the final review, and reviewed draft
Mieke L van Driel: screened searches, extracted data, assessed risk of bias, and reviewed draft
Chris B Del Mar: screened searches, extracted data, assessed risk of bias, and reviewed draft
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D E C L A R A T I O N S O F I N T E R E S T
Sharon L Sanders: none known
Sushil Agwan: none known
Mohamed Hassan: none known
Mieke L van Driel: none known
Chris B Del Mar: none known
S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Acute Respiratory Infections Review Group, Australia.
• Centre for Research in Evidence Based Practice, Australia.
External sources
• No external funding received, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
New authors joined the review (SLS, SA, and MH).
We made several changes to the secondary outcomes specified in the protocol. We changed adverse effects of the treatments from being
a secondary outcome in the protocol to a primary outcome in the review. The protocol also specified secondary outcomes related to
the duration of ventilation and attendance in the intensive care unit. We included the secondary outcome “need for ventilation” in
addition to the existing “duration of ventilation” outcome in the review. We included the secondary outcome “need for intensive care
unit admission” and renamed the outcome “days admitted to the intensive care unit” to “duration of stay in the intensive care unit”.
We renamed the secondary outcome “oxygen dependence” to “need for supplemental oxygen” and “duration of supplemental oxygen”.
We added the secondary outcomes related to need for mechanical ventilation, supplemental oxygen, and intensive care unit admission,
as we felt these were patient-important outcomes. We also identified the limitation in duration-related outcomes. Duration data were
only available for those children requiring mechanical ventilation, supplemental oxygen, or intensive care admission. This means the
comparisons between the interventions (immunoglobulins and placebo) were not randomised comparisons, and the outcomes are at
risk of selection bias. The need for ventilation, supplemental oxygen, and intensive care unit admission outcomes are randomised
comparisons.
We used GRADE to assess the certainty of the body of evidence and included a ’Summary of findings’ table. We did not contact trial
authors for missing trial information or unpublished studies as was intended when the protocol was written due to resource constraints.
Missing data due to losses to follow-up or protocol deviation were minimal; we took missing data into account in the ’Risk of bias’
assessment and did not apply any imputation measures as intended in the protocol. We expressed dichotomous outcomes as risk ratios
rather than odds ratios as stated in the protocol for their ease of interpretation.
We were unable to conduct prespecified subgroup analysis due to lack of data.
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